Use of soluble TREM-1 levels to identify subjects likely to respond to anti-inflammatory therapy
An in vitro method for identifying subjects with acute inflammatory disorders by measuring sTREM-1 levels addresses the need for personalized treatment by determining susceptibility to TREM-1 inhibitors, enhancing therapy effectiveness for SIRS, sepsis, and septic shock.
Patent Information
- Application Number
- JP2021542268
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-09-28
- Filing Date
- 2019-09-27
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2039-09-27
AI Technical Summary
Current treatments for acute inflammatory disorders such as Systemic Inflammatory Response Syndrome (SIRS), sepsis, and septic shock lack specificity, and there is a need to identify human subjects susceptible to therapies targeting the TREM-1 pathway, particularly TREM-1 inhibitors.
An in vitro method for identifying human subjects with acute inflammatory disorders by measuring soluble TREM-1 (sTREM-1) levels on bone marrow cells and comparing them to a predetermined value, indicating susceptibility to TREM-1 inhibitors.
Enables the identification of subjects likely to respond to TREM-1 inhibitors, potentially improving treatment outcomes for SIRS, sepsis, and septic shock by personalizing therapy based on sTREM-1 levels.
Smart Images

Figure 0007593644000014 
Figure 0007593644000015 
Figure 0007593644000016
Abstract
Description
[Technical field]
[0001] The present invention relates to the treatment of inflammatory disorders, preferably acute inflammatory disorders, in human subjects, in particular in a subpopulation of human subjects susceptible to a therapy, in particular to a TREM-1 inhibitor.Accordingly, the present invention relates to a method for identifying a human subject suffering from an inflammatory disorder, preferably an acute inflammatory disorder such as systemic inflammatory response syndrome (SIRS), sepsis or septic shock, and susceptible to a therapy, in particular to a TREM-1 inhibitor. [Background technology]
[0002] Systemic inflammatory response syndrome (SIRS) is characterized by systemic inflammation and widespread tissue damage. SIRS can occur as a response to non-specific injury of either infectious or non-infectious origin. Examples of injury of non-infectious origin include, but are not limited to, trauma, burn, pancreatitis, autoimmune disease, and surgery. Examples of injury of infectious origin include bacterial infection, fungal infection, and viral infection.
[0003] Sepsis is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Singer et al., JAMA. 2016 Feb 23;315(8):801-10). Thus, sepsis occurs when the body's response to infection injures its own tissues and organs, ultimately leading to death in 30-50% of cases (Fleischmann et al., Dtsch Arztebl Int. 2016 Mar 11;113(10):159-66). Furthermore, many survivors suffer from post-septic syndrome, with reports of increased sensory, integumentary, digestive, respiratory, chest pain, renal and musculoskeletal problems following sepsis (Huang et al., Int J Qual Health Care. 2018 Jun 19). According to the World Health Organization, it is estimated that sepsis affects more than 30 million people worldwide annually, potentially leading to death in 6 million cases.
[0004] Septic shock is defined as a subset of sepsis, in which particularly severe cardiovascular, cellular, and metabolic abnormalities are associated with a higher risk of mortality than sepsis alone (Singer et al., JAMA. 2016 Feb 23;315(8):801-10). Clinically, patients with septic shock can be identified as those with sepsis who (i) suffer from persistent hypotension after adequate fluid resuscitation requiring the use of vasopressors to maintain a mean blood pressure of 65 mmHg or higher, and (ii) have serum lactate levels above 2 mmol / L (Shankar-Hari et al., JAMA. 2016 Feb 23;315(8):775-87).
[0005] Currently, there is no specific causative treatment for sepsis or septic shock. Patient management therefore relies primarily on early recognition, allowing for rapid initiation of correct therapeutic measures, such as administration of appropriate antibiotics, source control measures if required, and resuscitation with intravenous fluids and vasoactive drugs if required (Cohen et al., Lancet Infect Dis. 2015 May;15(5):581-614). Previous attempts to develop treatments, such as endotoxin and TLR-targeted therapies, have been unsuccessful (Cuvier et al., Br J Clin Pharmacol. 2018 June 8).
[0006] Recently, applicants have developed therapeutics targeting the TREM-1 (triggering receptor expressed on myeloid cells-1) pathway. TREM-1 is an immune receptor expressed by innate immune cells (monocytes / macrophages, neutrophils, platelets, dendritic cells) and endothelial cells. Activation of TREM-1 leads to the production of cytokines and chemokines along with rapid neutrophil degranulation and oxidative burst. The function of TREM-1 is to regulate / amplify, rather than activate / initiate, inflammation to trigger an abundant immune response by synergizing with pathogen recognition receptors (PRRs) such as Toll-like receptors (TLRs). In particular, the TREM-1 pathway is involved in the pathophysiology of sepsis and septic shock. Thus, the applicant has shown that TREM-1 inhibitors, i.e. short TLT-1 (TREM-like transcript-1) peptides that inhibit TREM-1 activity, can be used to treat inflammatory disorders, in particular acute inflammatory disorders such as systemic inflammatory response syndrome (SIRS), sepsis or septic shock (WO2011 / 124685).TLT-1 (Trem-like transcript-1) is a receptor that is a member of the TREM family and is expressed exclusively by megakaryocytes and platelets.
[0007] However, in order for TREM-1 inhibitors to have the greatest therapeutic effect in treating acute inflammatory disorders such as SIRS, sepsis, or septic shock, there remains a need to identify human subjects suffering from acute inflammatory disorders that are amenable to therapy, particularly to TREM-1 inhibitors. In particular, there remains a need to identify human subjects suffering from acute inflammatory disorders such as SIRS, sepsis, or septic shock that are amenable to therapy, particularly to TLT-1 peptides that inhibit TREM-1 activity.
[0008] Applicants have now shown that by measuring levels of soluble TREM-1 (sTREM-1) in biological samples from human subjects suffering from septic shock and comparing those measured sTREM-1 levels to a predefined sTREM-1 value, it is possible to identify human subjects suffering from septic shock who are likely to respond to a TREM-1 inhibitor. In particular, Applicants have shown that human subjects suffering from septic shock who have circulating levels of sTREM-1 higher than a predefined median sTREM-1 level in a reference population of human subjects suffering from septic shock are more likely to respond to, and therefore benefit from, administration of a TLT-1 peptide that inhibits TREM-1 activity.
[0009] The present invention therefore relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably an acute inflammatory disorder such as SIRS, sepsis or septic shock, and susceptible to a therapy, in particular a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value; c) identifying a human subject suffering from an inflammatory disorder, preferably an acute inflammatory disorder such as SIRS, sepsis or septic shock, in which the level of sTREM-1 measured in step a) is higher than a predetermined sTREM-1 value in step b), as likely to respond to a therapy, in particular a TREM-1 inhibitor. The present invention also relates to a therapeutic agent, preferably a TREM-1 inhibitor, for use in the treatment of an inflammatory disorder, preferably an acute inflammatory disorder such as SIRS, sepsis or septic shock, in a subject in need thereof, wherein a level of sTREM-1 measured in a biological sample from the subject and higher than a predetermined sTREM-1 value indicates that the subject is likely to respond to the therapeutic agent, preferably a TREM-1 inhibitor. Summary of the Invention [Problem to be solved by the invention]
[0010] Thus, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder susceptible to a therapy, preferably a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value; and c) identifying a human subject suffering from an inflammatory disorder in which the level of sTREM-1 measured in step a) is higher than a predetermined sTREM-1 value in step b) as likely to respond to a treatment, preferably a TREM-1 inhibitor.
[0011] In one embodiment, the predetermined sTREM-1 value in step b) is obtained from a reference population, hi one embodiment, the reference population is a population of human patients suffering from an inflammatory disorder, preferably systemic inflammatory response syndrome (SIRS), sepsis or septic shock.
[0012] In one embodiment, the predetermined sTREM-1 value in step b) is the median sTREM-1 value in a reference population, or the third quartile of sTREM-1 in a reference population.
[0013] In one embodiment, the level of sTREM-1 measured in step a) is a level measured before the start of therapy, preferably before administration of a TREM-1 inhibitor. In one embodiment, the level of sTREM-1 measured in step a) is measured within the first 24 hours after diagnosis or hospitalization of the human subject for an inflammatory disorder.
[0014] In one embodiment, the biological sample is a blood sample, a serum sample, or a plasma sample.
[0015] In one embodiment, the level of sTREM-1 measured in step a) is the protein level, preferably measured by ELISA, electrochemiluminescence immunoassay (ECLIA) or electrochemiluminescence (ECL), also called enzyme-linked fluorescence assay (ELFA).
[0016] In one embodiment, the treatment comprises the administration of a TREM-1 inhibitor, preferably selected from the group consisting of peptides inhibiting the function, activity or expression of TREM-1, antibodies directed to TREM-1 and / or sTREM-1, or to TREM-1 and / or sTREM-1 ligand, small molecules inhibiting the function, activity or expression of TREM-1, siRNAs directed to TREM-1, shRNAs directed to TREM-1, antisense oligonucleotides directed to TREM-1, ribozymes directed to TREM-1 and aptamers directed to TREM-1. In one embodiment, the treatment comprises the administration of a TREM-1 inhibitor, the TREM-1 inhibitor being a peptide targeting the sTREM-1 ligand, preferably a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12. In one embodiment, the treatment comprises the administration of a TREM-1 inhibitor, the TREM-1 inhibitor being a peptide having the amino acid sequence set forth in SEQ ID NO:9.
[0017] In one embodiment, the therapeutic is a TREM-1 inhibitor, preferably selected from the group consisting of a peptide that inhibits the function, activity or expression of TREM-1, an antibody directed to TREM-1 and / or sTREM-1 or to the TREM-1 and / or sTREM-1 ligand, a small molecule that inhibits the function, activity or expression of TREM-1, an siRNA directed to TREM-1, an shRNA directed to TREM-1, an antisense oligonucleotide directed to TREM-1, a ribozyme directed to TREM-1 and an aptamer directed to TREM-1. In one embodiment, the TREM-1 inhibitor is a peptide that inhibits the function, activity or expression of TREM-1 by targeting the TREM-1 ligand, preferably a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12. In one embodiment, the TREM-1 inhibitor is a peptide having the amino acid sequence set forth in SEQ ID NO:9.
[0018] In one embodiment, the inflammatory disorder is selected from the group comprising systemic inflammatory response syndrome (SIRS), sepsis and septic shock, preferably, the inflammatory disorder is septic shock.In one embodiment, the human subject suffers from organ dysfunction defined as an acute change in Sequential Organ Failure Assessment (SOFA) score of at least 2 points.
[0019] In one embodiment, a human subject suffering from SIRS, sepsis or septic shock susceptible to a therapy, preferably a TREM-1 inhibitor, is a human subject susceptible to having a reduced Sequential Organ Failure Assessment (SOFA) score after administration of a therapy, preferably after administration of a TREM-1 inhibitor. In one embodiment, a human subject suffering from septic shock susceptible to a therapy, preferably a TREM-1 inhibitor, is a human subject suffering from septic shock susceptible to reversing hypotensive shock within or after a period of administration of a therapy, preferably a TREM-1 inhibitor, where hypotensive shock reversal is defined as the absence of any vasopressor therapy for a 24 hour period. definition
[0020] In the present invention, the following terms have the following meanings:
[0021] The use of "about" before a number includes the value of that number plus or minus 10% or less. It is to be understood that the value to which the term "about" refers is itself also specifically and preferably disclosed.
[0022] "APACHE II" refers to "Acute Physiology and Chronic Health Evaluation II." APACHE II is a commonly used scoring system to assess the severity of disease and determine prognosis in adult patients admitted to intensive care units. APACHE II provides a general measure of disease severity using a point score ranging from 0 to 71 based on initial values of 12 routine physiological measurements (i.e., variables), age, and previous health conditions (Knaus et al., Crit Care Med. 1985 Oct;13(10):818-29).
[0023] "APACHEIII" stands for "Acute Physiology and Chronic Health Evaluation III." APACHEIII is a redefined scoring system from the APACHEII scoring system to more accurately predict the risk of hospital mortality in critically ill hospitalized adults (Knaus et al., Chest. 1991 Dec;100(6):1619-36). The APACHEIII scoring system is similar to the APACHEII scoring system, but several variables are added to those used in the APACHEII scoring system, resulting in 17 variables calculated into a point score ranging from 0 to 299.
[0024] "APACHEIV" refers to "Acute Physiology and Chronic Health Evaluation IV." APACHEIV is an improved and updated model for estimating short-term mortality risk as well as predicting length of intensive care unit (ICU) stay (Zimmerman et al., Crit Care Med. 2006 May;34(5):1297-310). The APACHEIV scoring system takes into account more variables, especially the effect of mechanical ventilation, thrombolysis, and sedation on the Glasgow Coma Scale, rescaled Glasgow Coma Scale, PaO2 / FiO2 ratio, and disease-specific subgroups. APACHEIV uses a point score ranging from 0 to 286.
[0025] "Electrochemiluminescence immunoassay (ECLIA)" refers to an immunoassay in which detection of a signal is based on electrochemiluminescence, a form of chemiluminescence in which an electrochemical reaction occurs prior to the light-emitting chemiluminescent reaction.
[0026] "Fluid therapy" refers to treatment aimed at restoring and / or maintaining normal volume and composition of bodily fluids, especially with regard to water and electrolyte balance. Fluid therapy is thus aimed at correcting and / or preventing volume and / or electrolyte deficiencies.
[0027] "Immunocompromised" refers to a subject who is impaired or completely lacks the ability to develop a normal immune response, for example to fight infection or cancer. Similarly, "immunocompromised" refers to a subject who is impaired in the ability to develop a normal immune response, for example to fight infection or cancer. "Immunosuppressed" refers to a subject who has reduced activation or effectiveness of the immune system, especially by administration of immunosuppressive therapy. For example, immunosuppression in a subject can be assessed by measuring PD-1 levels, measuring circulating IL-7 levels, or measuring HLA-DR.
[0028] "Measuring" or "measurement" or "detecting" or "detection" means assessing the presence, absence, quantity, or amount (which may be an effective amount) of a given substance, i.e., sTREM-1, in a biological sample from a human subject. As used herein, "measuring" or "measurement" or "detecting" or "detection" includes deriving a qualitative or quantitative concentration (e.g., blood or plasma concentration) of a substance, i.e., sTREM-1, in a biological sample and in a human subject.
[0029] As used herein, "organ dysfunction score" or "organ dysfunction scoring system" refers to the score used to assess organ dysfunction in human subjects, particularly those suffering from SIRS, sepsis or septic shock, upon admission, particularly to ICU or emergency room. Examples of organ dysfunction scores include, but are not limited to, SOFA score, qSOFA score, MODS (multiple organ dysfunction score), P-MODS (pediatric multiple organ dysfunction score), and LODS (logistic organ dysfunction system).
[0030] "qSOFA score" refers to the quick SOFA score (also known as quickSOFA). The qSOFA scoring system relies on three criteria: respiratory rate ≥ 22 breaths / min, impaired consciousness (Glasgow Coma Scale < 15), and systolic blood pressure ≥ 100 mmHg (Seymour et al., JAMA. 2016 Feb 23;315(8):762-74).
[0031] "Quantile(s)" refers to (a) a cut-off value(s) that divides the observations / measurements made in a population into groups of equal size, each group comprising an equal proportion (percentage) of the aforementioned observations / measurements. Thus, as used herein, "quantile(s)" refers to a cut-off sTREM-1 value(s) that divides the sTREM-1 levels measured in biological samples from each of the human subjects of a reference population into groups of equal size, each containing an equal proportion (percentage) of the measured sTREM-1 levels. In other words, "quantile(s)" refers to a cut-off sTREM-1 value above and below which are a given percentage of the sTREM-1 levels measured in the reference population. For example, as used herein, "quartile(s)" refers to three cut-off sTREM-1 values that divide the sTREM-1 levels measured in a reference population into four groups, each containing 25% of the sTREM-1 levels measured in the reference population. It should be noted that "quantile" may also refer to groups so defined by a cutoff value. For example, "quartile" may refer to four groups defined by three cutoff sTREM-1 values, thus dividing the sTREM-1 levels measured in a reference population. However, as used herein, unless otherwise specified, the term "quantile" refers to a cutoff value.
[0032] "SAPS" refers to "Simplified Acute Physiological Score." SAPS is a scoring system that reflects the risk of death in ICU patients. SAPS depends on 14 biological and clinical variables (Le Gall et al., Crit Care Med. 1984 Nov;12(11):975-7).
[0033] "SAPSII" refers to "Simplified Acute Physiological Score II." SAPSII is a scoring system for estimating in-hospital mortality in adult patients admitted to the intensive care unit (ICU). SAPSII includes 17 variables: 12 physiological variables, age, type of admission, and three variables related to underlying disease (Le Gall et al., JAMA. 1993 Dec 22-29;270(24):2957-63). SAPSII uses a point score ranging from 0 to 163.
[0034] "SAPS3" refers to "Simplified Acute Physiology Score III." SAPS3 is a scoring system for predicting hospital mortality in patients admitted to the intensive care unit (ICU) (Metnitz et al., Intensive Care Med. 2005 October;31(10):1336-1344 and Moreno et al., Intensive Care Med. 2005 October;31(10):1345-55). SAPS3 is based on 20 different variables.
[0035] As used herein, "severity score" or "severity scoring system" refers to the score used to assess the disease severity and / or prognosis of human subjects, particularly those suffering from SIRS, sepsis or septic shock, upon admission to ICU or emergency room. Examples of severity scores include, but are not limited to, APACHE II score, APACHE III score, APACHE IV score, SAPS score, SAPS II score, and SAPS3 score.
[0036] As used herein, "SIRS, sepsis or septic shock therapy" refers to a therapy administered to a subject in need thereof for the treatment of SIRS, sepsis or septic shock. In one embodiment, the SIRS, sepsis or septic shock therapy is an immunomodulatory or anti-inflammatory therapy. Examples of immunomodulatory or anti-inflammatory therapy include, but are not limited to, checkpoint inhibitors such as anti-PD-1, anti-PD-L1 and anti-CTLA4, TLR (Toll-like receptor) inhibitors, cytokine inhibitors such as anti-cytokine or anti-cytokine receptors (e.g., IL-1RA, an interleukin-1 receptor antagonist), inhibitors of immunostimulants such as G-CSF (granulocyte colony stimulating factor), IL-7 (interleukin-7), CD28 antagonist peptides and antibodies, particularly monoclonal antibodies against CD28, and cell therapy such as adoptive cell therapy. In one embodiment, the SIRS, sepsis or septic shock therapy is an angiogenesis inhibitor, particularly an angiopoietin-2 (Ang-2 or Ang2) inhibitor. In one embodiment, the SIRS, sepsis or septic shock therapy is a TREM-1 inhibitor. In one embodiment, the TREM-1 inhibitor is a peptide that targets a TREM-1 ligand, preferably a peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12.
[0037] "Shock" or "hypotension shock" or "maldistribution shock" refers to reduced or inadequate perfusion that impairs organ function and is generally associated with a fall in arterial blood pressure. Hypotension shock may not respond to fluid resuscitation and may require vasopressor therapy to increase arterial blood pressure, restore effective tissue perfusion, and normalize cellular metabolism.
[0038] As used herein, "shock reversal" or "hypotensive shock reversal" is defined as the absence of any vasopressor therapy for at least 24 hours (i.e., no need to resume vasopressor therapy 24 hours after the end of vasopressor therapy). In one embodiment, shock reversal can occur within the administration period of SIRS, sepsis, or septic shock therapy. In one embodiment, shock reversal can occur 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, or 72 hours after the start of administration of SIRS, sepsis, or septic shock therapy. In one embodiment, shock reversal can occur after the administration period of SIRS, sepsis, or septic shock therapy. In one embodiment, shock reversal can occur 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 66, or 72 hours after the end of administration of SIRS, sepsis, or septic shock therapy.
[0039] "SOFA score" refers to the Sequential Organ Failure Assessment (SOFA) score (originally called the Sepsis-Associated Organ Failure Assessment), which is commonly used to assess the presence of organ dysfunction. The SOFA scoring system (Vincent et al., Crit Care Med. 1998 Nov;26(11):1793-800) relies on assessment of the respiratory system (i.e., PaO2 / FiO2 (mmHg)), neurological system (i.e., Glasgow Coma Scale), cardiovascular system (i.e., mean arterial pressure or administration of vasopressors as required), liver function (i.e., bilirubin (mg / dL or μmol / L)), coagulation (i.e., platelet count), and renal function (i.e., creatinine (mg / dL or μmol / L) or urine volume (mL / d)).
[0040] "Standard of care" refers to the care routinely provided to patients suffering from inflammatory disorders, particularly systemic inflammatory response syndrome (SIRS), sepsis, or septic shock. In one embodiment, the patient suffers from septic shock, and the standard of care includes at least one of antimicrobial therapy, fluid therapy, vasopressor therapy, cardiovascular support, respiratory support, renal support, and sedation.
[0041] "TREM-1" means "trigger receptor-1 expressed on myeloid cells". TREM-1 is a membrane-bound glycoprotein receptor belonging to the Ig superfamily, specifically expressed on myeloid cells. TREM-1 activates downstream signaling pathways with the help of an adaptor protein called DAP12. TREM-1 is composed of three distinct domains, an Ig-like structure (mainly involved in ligand binding), a transmembrane portion, and a cytoplasmic tail that binds DAP12. Unless otherwise indicated, the TREM-1 protein has the amino acid sequence set forth in SEQ ID NO: 1, which corresponds to UniProtKB / Swiss-Prot accession number Q9NP99-1, last revised on October 1, 2000, and UniProtKB accession number Q38L15-1, last revised on November 22, 2005. Several transcripts are known for TREM-1. The transcript commonly referred to as TREM1-201 (Transcript ID ensemble ENST00000244709.8) encodes the amino acid sequence set forth in SEQ ID NO: 1. The transcript commonly referred to as TREM1-202, also known as TREM-1 isoform 2 (Ensemble Transcript ID ENST00000334475.10), encodes the amino acid sequence set forth in SEQ ID NO: 2 (corresponding to UniProtKB / Swiss-Prot accession number Q9NP99-2). The transcript commonly referred to as TREM1-207, also known as TREM-1 isoform 3 (Ensemble Transcript ID ENST00000591620.1), encodes the amino acid sequence set forth in SEQ ID NO: 3 (corresponding to UniProtKB / Swiss-Prot accession number Q9NP99-3). The transcript commonly referred to as TREM1-204 (ensemble transcript ID ENST00000589614.5) encodes the amino acid sequence set forth in SEQ ID NO: 4 (corresponding to UniProtKB / Swiss-Prot accession number K7EKM5-1, last revised on January 9, 2013).
[0042] "sTREM-1" in "soluble triggering receptor-1 expressed in myeloid cells" refers to a soluble form of TREM-1 that does not have the transmembrane and intracellular domains of TREM-1. Thus, in one embodiment, sTREM-1 corresponds to a soluble form of the extracellular domain of TREM-1. Soluble TREM-1 can be generated by proteolytic cleavage of the TREM-1Ig-like ectodomain from membrane-anchored TREM-1 by matrix metalloproteinases (Gomez-Pina et al., J Immunol. 2007 Sep. 15;179(6):4065-73). Thus, in one embodiment, sTREM-1 corresponds to a truncated TREM-1 released from the membrane of myeloid cells, particularly activated myeloid cells. It has also been suggested that sTREM-1 results from alternative splicing of TREM-1 mRNA. A TREM-1 splice variant was characterized in 2015 by Baruah et al. (J Immunol. 2015 Dec 15;195(12):5725-31) and was found to be secreted from primary and secondary human neutrophil granules. Thus, in one embodiment, sTREM-1 corresponds to a TREM-1 splice variant, in particular the TREM-1 transcript commonly referred to as TREM1-202, also known as TREM-1 isoform 2, which encodes the amino acid sequence set forth in SEQ ID NO:2.
[0043] As used herein, "median sTREM-1" refers to a given sTREM-1 value obtained from a reference population that divides the sTREM-1 levels measured in the reference population into two groups, each containing 50% of the sTREM-1 levels measured in the reference population.
[0044] As used herein, "sTREM-1 tertile" refers to a given sTREM-1 value obtained from a reference population that divides the sTREM-1 levels measured in the reference population into three groups, each containing one-third of the sTREM-1 levels measured in the reference population. In one embodiment, the sTREM-1 tertile is the last sTREM-1 tertile (i.e., the second tertile of sTREM-1) and corresponds to a sTREM-1 value below which two-thirds of the sTREM-1 levels measured in the reference population lie and above which one-third of the sTREM-1 levels measured in the reference population lie.
[0045] As used herein, "sTREM-1 quartile" refers to a given sTREM-1 value obtained from a reference population that divides the sTREM-1 levels measured in the reference population into four groups, each containing 25% of the sTREM-1 levels measured in the reference population. In one embodiment, the sTREM-1 quartile is the last sTREM-1 quartile (i.e., the third quartile of sTREM-1, also referred to as Q3), and corresponds to the sTREM-1 value below which 75% of the sTREM-1 levels measured in the reference population are present and above which 25% of the sTREM-1 levels measured in the reference population are present.
[0046] As used herein, "sTREM-1 quintile" refers to a given sTREM-1 value obtained from a reference population that divides the sTREM-1 levels measured in the reference population into five groups, each containing 20% of the sTREM-1 levels measured in the reference population. In one embodiment, the sTREM-1 quintile is the last sTREM-1 quintile (i.e., the fourth sTREM-1 quintile) and corresponds to the sTREM-1 value below which 80% of the sTREM-1 levels measured in the reference population are present and above which 20% of the sTREM-1 levels measured in the reference population are present.
[0047] As used herein, "sTREM-1 decile" refers to a given sTREM-1 value obtained from a reference population that divides the sTREM-1 levels measured in the reference population into 10 groups, each containing 10% of the sTREM-1 levels measured in the reference population. In one embodiment, the sTREM-1 decile is the last sTREM-1 decile (i.e., the 9th sTREM-1 decile) and corresponds to the sTREM-1 value below which 90% of the sTREM-1 levels measured in the reference population lie and above which 10% of the sTREM-1 levels measured in the reference population lie.
[0048] As used herein, "sTREM-1 percentile" refers to a predefined sTREM-1 value obtained from a reference population, which divides the sTREM-1 levels measured in the reference population into groups corresponding to a predefined percentage of the sTREM-1 levels measured in the reference population.Thus, as used herein, a sTREM-1 percentile is a predefined sTREM-1 value obtained from a reference population, below which a predefined percentage of the sTREM-1 levels measured in the reference population exists.For example, a 40th percentile is a sTREM-1 value obtained from a reference population, below which 40% of the sTREM-1 levels measured in the reference population exists.
[0049] A "therapeutically effective amount" or "therapeutically effective dose" refers to an amount or dosage of a therapy (preferably a TREM-1 inhibitor) intended to (1) delay or prevent the onset of an inflammatory disorder (preferably SIRS, sepsis or septic shock) in a human subject, (2) reduce the severity or incidence of an inflammatory disorder (preferably SIRS, sepsis or septic shock), (3) slow or stop the progression, exacerbation or worsening of one or more symptoms of an inflammatory disorder (preferably SIRS, sepsis or septic shock) affecting a human subject, (4) result in the amelioration of a symptom of an inflammatory disorder (preferably SIRS, sepsis or septic shock) affecting a human subject, or (5) cure an inflammatory disorder (preferably SIRS, sepsis or septic shock) affecting a human subject, without causing significant negative or harmful side effects to the human subject. In one embodiment, the administration of a therapeutically effective dose (or amount) of a therapy, preferably a TREM-1 inhibitor, to a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, is aimed at inducing at least one of the following in the subject: - preferably reversal of hypotensive shock during or after the administration period of therapy (preferably a TREM-1 inhibitor), e.g., over 6 hours, 12 hours, 18 hours or 24 hours after the end of administration, where reversal of hypotensive shock is defined as the absence of any vasopressor therapy for at least 24 hours (i.e., no need to restart vasopressor therapy within 24 hours after the end of vasopressor therapy), - A reduction in severity scores (such as APACHEII score, APACHEIII score, APACHEIV score, SAPS score, SAPSII score, or SAPS3 score) used to evaluate the severity and / or prognosis of a disease in a subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, upon admission to the ICU or emergency room; - A reduction in organ dysfunction scores (such as SOFA score, qSOFA score, MODS (Multiple Organ Dysfunction Score), P-MODS (Pediatric Multiple Organ Dysfunction Score), or LODS (Logistic Organ Dysfunction System)) used to assess the presence of organ dysfunction in human subjects suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, upon admission to an ICU or emergency room, - a decrease in the SOFA score and / or qSOFA score, preferably with reference to the SOFA score and / or qSOFA score assessed at the time of admission to the ICU or emergency room or before the start of administration of the therapy, in particular over 1, 2, 3, 4, 5, 6 or 7 days after the start of administration of the therapy (preferably a TREM-1 inhibitor), in one embodiment the decrease in the SOFA score is a decrease of at least 1 point (also referred to as delta-1 point or ΔSOFA-1 point), preferably at least 1.5 points, in particular on the 3rd or 5th day after the start of administration of the therapy, preferably with reference to the SOFA score and / or qSOFA score assessed at the time of admission to the ICU or emergency room or before the start of administration of the therapy, - a reduction in the need for cardiovascular support, e.g. preferably with reference to the need for cardiovascular support upon admission to the ICU or emergency room or prior to the start of the treatment, in particular the use of vasopressor therapy over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment (preferably a TREM-1 inhibitor); - a reduction in the need for respiratory support, e.g. preferably with reference to the need for respiratory support upon admission to the ICU or emergency room or before the start of the treatment, in particular the use of invasive mechanical ventilation (IMV) over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment, preferably a TREM-1 inhibitor, - a reduced need for renal support, e.g. preferably with reference to the need for renal support at the time of admission to the ICU or emergency room or before the start of the treatment, in particular the use of continuous or non-continuous renal replacement therapy, also called RRT (such as dialysis), over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment (preferably a TREM-1 inhibitor); - a reduced risk of reinfection, in particular 28 days, 90 days or 365 days after a first inflammatory disorder, in particular a first infection causing an inflammatory disorder, - absence of reinfection, especially 28 days, 90 days or 365 days after the initial inflammatory disorder, especially after the initial infection causing the inflammatory disorder, - a reduced risk of re-admission, particularly at 28, 90 or 365 days after the first inflammatory disorder, particularly the first infection causing the inflammatory disorder; - No readmission, specifically no readmission within 28, 90 or 365 days after the initial admission; - an increased chance of survival, in particular surviving 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years after initiation of administration of a therapy, preferably a TREM-1 inhibitor, in one embodiment the chance of survival, in particular in subjects with multiple comorbidities, is assessed with the Charlson Comorbidity Index (CCI), and an increased chance of survival at 10 years corresponds to a decrease in the Charlson Comorbidity Index, preferably with reference to the CCI assessed at the time of admission to the ICU or emergency room or before initiation of administration of the therapy, - a reduced risk of sepsis-related death, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - A reduction in the risk of all-cause death, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - a reduced risk of post-septic or post-shock morbidity, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); -Improved quality of life (especially post-sepsis or post-shock quality of life), which can be assessed, for example, by evaluation of survival rates and quality-adjusted life years (QALYs), as estimated from the EuroQoL Quality of Life Scale, commonly known as EQ5D. For example, a Health-Related Quality of Life (HRQoL) score of EQ 5D 5L (a 5-level EQ-5D version) can be calculated and converted into a utility score, particularly at 3, 6, 9, 12, 18, 24 or 36 months after the start of the treatment. - a reduction in the levels of inflammatory markers such as, for example, CRP or IL6, IL-8, IL-10, MCP-1 and TNF-α, in particular over 1, 2, 3, 4, 5, 6 or 7 days after initiation of treatment with a therapy (preferably a TREM-1 inhibitor), preferably with reference to levels assessed upon admission to the ICU or emergency room or before initiation of treatment with a therapy, or - A reduction in levels of markers of endothelial damage such as, for example, Ang-2, VCAM-1, VGEFR-1 and E-selectin, preferably relative to levels assessed upon admission to the ICU or emergency room or prior to initiation of therapy, in particular over 1, 2, 3, 4, 5, 6 or 7 days after initiation of therapy (preferably a TREM-1 inhibitor).
[0050] A therapeutically effective amount of a therapy, preferably a TREM-1 inhibitor, may be administered for a prophylactic or preventative effect prior to the onset of an inflammatory disorder, preferably SIRS, sepsis or septic shock, prior to diagnosis of an inflammatory disorder, preferably SIRS, sepsis or septic shock, prior to admission to an ICU or emergency room, or prior to the initiation of vasopressor therapy. Alternatively or additionally, a therapeutically effective amount of a therapy, preferably a TREM-1 inhibitor, may be administered for a therapeutic effect after the onset of an inflammatory disorder, preferably SIRS, sepsis or septic shock, after diagnosis of an inflammatory disorder, preferably SIRS, sepsis or septic shock, after admission to an ICU or emergency room, or after the initiation of vasopressor therapy.
[0051] "TLT-1" refers to TREM-like transcript-1. TLT-1 is a receptor that is a member of the TREM family and is expressed exclusively by megakaryocytes and platelets. TLT-1 contains a v-set Ig type extracellular domain, a transmembrane region, and a cytoplasmic tail that contains an immunoreceptor tyrosine-based inhibitory motif (ITIM) and a polyproline-rich domain.
[0052] "Treating" or "treatment" refers to therapeutic treatment, prophylactic or preventative measures, or both, the purpose of which is to prevent, slow down (alleviate) or cure the targeted pathological condition or disorder, i.e., inflammatory disorder, preferably SIRS, sepsis or septic shock. In one embodiment of the present invention, "treating" or "treatment" refers to therapeutic treatment. In another embodiment of the present invention, "treating" or "treatment" refers to prophylactic or preventative treatment. In yet another embodiment of the present invention, "treating" or "treatment" refers to both prophylactic (or preventative) treatment and therapeutic measures. Treatment is required when an inflammatory disorder, preferably SIRS, sepsis or septic shock, is already present, as well as when an inflammatory disorder, preferably SIRS, sepsis or septic shock, is likely to develop, or when an inflammatory disorder, preferably SIRS, sepsis or septic shock, should be prevented. A human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, after being administered a therapeutically effective amount of a therapy, preferably a TREM-1 inhibitor, is successfully "treated" if the human subject exhibits at least one of the following: - reversal of hypotensive shock, preferably during or after the administration period of therapy (preferably a TREM-1 inhibitor), e.g., for 6, 12, 18 or 24 hours after the end of administration, defined as the absence of any vasopressor therapy for at least 24 hours (i.e., no need to restart vasopressor therapy within 24 hours after the end of vasopressor therapy), - A reduction in severity scores (such as APACHEII score, APACHEIII score, APACHEIV score, SAPSII score, or SAPS3 score) used to evaluate the severity and / or prognosis of a disease in a subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, upon admission to the ICU or emergency room; - A reduction in organ dysfunction scores (such as SOFA score, qSOFA score, MODS (Multiple Organ Dysfunction Score), P-MODS (Pediatric Multiple Organ Dysfunction Score), or LODS (Logistic Organ Dysfunction System)) used to assess the presence of organ dysfunction in human subjects suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, upon admission to an ICU or emergency room, - a decrease in the SOFA score and / or qSOFA score, preferably with reference to the SOFA score and / or qSOFA score assessed at the time of admission to the ICU or emergency room or before the start of administration of the therapy, in particular over 1, 2, 3, 4, 5, 6 or 7 days after the start of administration of the therapy (preferably a TREM-1 inhibitor), in one embodiment the decrease in the SOFA score is a decrease of at least 1 point (also referred to as delta-1 point or ΔSOFA-1 point), preferably at least 1.5 points, in particular on the 3rd or 5th day after the start of administration of the therapy, preferably with reference to the SOFA score and / or qSOFA score assessed at the time of admission to the ICU or emergency room or before the start of administration of the therapy, - a reduction in the need for cardiovascular support, e.g. preferably with reference to the need for cardiovascular support upon admission to the ICU or emergency room or prior to the start of the treatment, in particular the use of vasopressor therapy over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment (preferably a TREM-1 inhibitor); - a reduction in the need for respiratory support, e.g. preferably with reference to the need for respiratory support upon admission to the ICU or emergency room or before the start of the treatment, in particular the use of invasive mechanical ventilation (IMV) over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment, preferably a TREM-1 inhibitor, - a reduced need for renal support, e.g. preferably with reference to the need for renal support at the time of admission to the ICU or emergency room or before the start of the treatment, in particular the use of continuous or non-continuous renal replacement therapy, also called RRT (such as dialysis), over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment (preferably a TREM-1 inhibitor); - a reduced risk of reinfection, in particular 28 days, 90 days or 365 days after a first inflammatory disorder, in particular a first infection causing an inflammatory disorder, - absence of reinfection, especially 28 days, 90 days or 365 days after the initial inflammatory disorder, especially after the initial infection causing the inflammatory disorder, - a reduced risk of re-hospitalisation, particularly re-infection 28, 90 or 365 days after the initial inflammatory disorder, particularly the initial infection causing the inflammatory disorder; - No readmission, specifically no readmission within 28, 90 or 365 days after the initial admission; - an increased chance of survival, in particular surviving 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years after initiation of administration of a therapy (preferably a TREM-1 inhibitor), in one embodiment the chance of survival, in particular in subjects with multiple comorbidities, is assessed with the Charlson Comorbidity Index (CCI), and an increased chance of survival at 10 years corresponds to a decrease in the Charlson Comorbidity Index, preferably with reference to the CCI assessed at the time of admission to the ICU or emergency room or before initiation of administration of the therapy, - a reduced risk of sepsis-related death, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - A reduction in the risk of all-cause death, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - a reduced risk of post-septic or post-shock morbidity, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - improved quality of life, especially post-sepsis or post-shock quality of life, which can be assessed, for example, by assessment of survival and quality-adjusted life years (QALYs) estimated from EQ5D. For example, a health-related quality of life (HRQoL) score of EQ 5D 5L can be calculated and converted into a utility score, especially at 3, 6, 9, 12, 18, 24 or 36 months after the start of the treatment. - a reduction in the levels of inflammatory markers such as, for example, CRP or IL6, IL-8, IL-10, MCP-1 and TNF-α, in particular over 1, 2, 3, 4, 5, 6 or 7 days after initiation of treatment with a therapy (preferably a TREM-1 inhibitor), preferably with reference to levels assessed upon admission to the ICU or emergency room or before initiation of treatment with a therapy, or - A reduction in levels of markers of endothelial damage such as, for example, Ang-2, VCAM-1, VGEFR-1 and E-selectin, preferably with reference to levels assessed upon admission to the ICU or emergency room or prior to initiation of therapy, in particular over 1, 2, 3, 4, 5, 6 or 7 days after initiation of therapy (preferably a TREM-1 inhibitor).
[0053] The above parameters for assessing successful treatment and disease improvement are readily measurable by routine procedures familiar to physicians.
[0054] "TREM-1 inhibitor" refers to an active agent capable of inhibiting the function, activity or expression of TREM-1. Examples of TREM-1 inhibitors include, but are not limited to, peptides that inhibit the function, activity or expression of TREM-1, antibodies directed to TREM-1 and / or sTREM-1, or TREM-1 and / or sTREM-1 ligands, small molecules that inhibit the function, activity or expression of TREM-1, siRNAs directed to TREM-1, shRNAs directed to TREM-1, antisense oligonucleotides directed to TREM-1, ribozymes directed to TREM-1, and aptamers directed to TREM-1.
[0055] "Vasopressor therapy" refers to therapies used to treat shock, i.e., hypotensive shock, defined as reduced or inadequate perfusion that impairs organ function and is generally associated with a fall in arterial blood pressure. Vasopressor therapy is indicated, particularly when hypotension does not respond to fluid resuscitation. Vasopressor therapy aims to increase arterial blood pressure, maintain adequate blood pressure, restore effective tissue perfusion, and normalize cellular metabolism. Examples of vasopressor therapy include, but are not limited to, administering vasoactive catecholamine hormones such as norepinephrine, dopamine, epinephrine, vasopressin, and / or phenylephrine. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0056] The present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder that is susceptible to a therapeutic treatment, the method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value; and c) identifying a human subject suffering from an inflammatory disorder in which the level of sTREM-1 measured in step a) is higher than a predetermined sTREM-1 value in step b) as likely to respond to the therapy.
[0057] In other words, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder that is likely to respond to a therapeutic treatment, wherein a level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) measured in a biological sample from the human subject that is higher than a predetermined sTREM-1 value indicates that the human subject is likely to respond to the therapeutic treatment.
[0058] The present invention also relates to an in vitro method for selecting a human subject suffering from an inflammatory disorder for treatment, preferably with a TREM-1 inhibitor, the method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value; and c) selecting a human subject suffering from an inflammatory disorder in which the level of sTREM-1 measured in step a) is higher than the predetermined sTREM-1 value in step b) for treatment with a therapy, preferably a TREM-1 inhibitor.
[0059] Another object of the present invention is a therapeutic agent, preferably a TREM-1 inhibitor, for use in treating an inflammatory disorder in a subject in need thereof, wherein a level of sTREM-1 measured in a biological sample from the subject that is higher than a predetermined sTREM-1 value indicates that the subject is likely to respond to the therapeutic agent, preferably a TREM-1 inhibitor.
[0060] Thus, the present invention also relates to a method for treating an inflammatory disorder in a human subject identified as susceptible to a therapy, preferably a TREM-1 inhibitor, comprising: A human subject suffering from an inflammatory disorder amenable to therapy, preferably a TREM-1 inhibitor, a) obtaining a biological sample from a human subject and measuring a level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in the biological sample; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value; c) identifying human subjects suffering from an inflammatory disorder, in which the level of sTREM-1 measured in step a) is higher than the predefined sTREM-1 value in step b), by identifying such subjects as likely to respond to a treatment, preferably a TREM-1 inhibitor; administering a therapy, preferably a TREM-1 inhibitor, to a subject suffering from an inflammatory disorder identified as being susceptible to a therapy, preferably a TREM-1 inhibitor, thereby treating the inflammatory disorder in the human subject identified as being susceptible to a therapy, preferably a TREM-1 inhibitor.
[0061] TREM-1 (triggering receptor-1 expressed on myeloid cells) is a glycoprotein receptor belonging to the Ig superfamily that is expressed especially on myeloid cells. sTREM-1 is a soluble form of TREM-1 that does not contain the transmembrane and intracellular domains of TREM-1. Without wishing to be bound by theory, applicants suggest that engagement of PRRs (pathogen recognition receptors), such as Nod-like receptors (NLRs) and Toll-like receptors (TLRs), induces upregulation of TREM-1 expression and / or its recruitment and clustering at the cell membrane, leading to its dimerization and multimerization. Activation of the above NLRs and TLRs can occur by ligating DAMPs (danger associated molecular patterns) or PAMPs (pathogen associated molecular patterns). In particular, activation of NLRs and TLRs can occur under sterile inflammatory conditions by ligating DAMPs (danger associated molecular patterns) and / or alarmins, or under infectious conditions by ligating PAMPs (pathogen associated molecular patterns). This activation of NLRs and TLRs induces the upregulation of proteases, particularly metalloproteinases, which, among other targets, induce the proteolytic cleavage of membrane-anchored TREM-1 to release soluble TREM-1 (Gomez-Pina et al., J Immunol. 2007 Sep. 15;179(6):4065-73). Proteolytic cleavage is dependent on dimerization of the TREM-1 receptor. Thus, sTREM-1 is released from the membrane of myeloid cells, particularly activated myeloid cells, and release of sTREM-1 is a marker of TREM-1 activation. In one embodiment, sTREM-1 corresponds to a soluble form of the extracellular domain of TREM-1. In one embodiment, sTREM-1 corresponds to truncated TREM-1 released from the membrane of myeloid cells, particularly activated myeloid cells.
[0062] sTREM-1 may also result from alternative splicing of TREM-1 mRNA. TREM-1 splice variants were characterized in 2015 by Baruah et al. (J Immunol. 2015 Dec 15;195(12):5725-31) and found to be secreted from primary and secondary human neutrophil granules. In one embodiment, sTREM-1 corresponds to a TREM-1 splice variant. In one embodiment, sTREM-1 corresponds to the TREM-1 transcript commonly referred to as TREM1-202, also known as TREM-1 isoform 2, which encodes the amino acid sequence set forth in SEQ ID NO:2. Thus, in one embodiment, sTREM-1 has the amino acid sequence set forth in SEQ ID NO:2 (MRKTRLWGLLWMLFVSELRAATKLTEEKYELKEGQTLDVKCDYTLEKFASSQKAWQIIRDGEMPKTLACTERPSKNSHPVQVGRIILEDYHDHGLLRVRMVNLQVEDSGLYQCVIYQPPKEPHMLFDRIRLVVTKGFRCSTLSFSWLVDS).
[0063] In one embodiment, sTREM-1 has the amino acid sequence set forth in SEQ ID NO:5 (ATKLTEEKYELKEGQTLDVKCDYTLEKFASSQKAWQIIRDGEMPKTLACTERPSKNSHPVQVGRIILEDYHDHGLLRVRMVNLQVEDSGLYQCVIYQPPKEPHMLFDRIRLVVTKGFSGTPGSNENSTQNVYKIPPTTTKALCPLYTSPRTVTQAPPKSTADVSTPDSEINLTNVTDIIRVPVFN), which corresponds to amino acids 21 to 205 of SEQ ID NO:1.
[0064] In another embodiment, sTREM-1 has the amino acid sequence set forth in SEQ ID NO:6 (LKEGQTLDVKCDYTLEKFASSQKAWQIIRDGEMPKTLACTERPSKNSHPVQVGRIILEDYHDHGLLRVRMVNLQVEDSGLYQCVIYQPPKEPHMLFDRIRLVVTKGFSGTPGSNENSTQNVYKIPPTTTKALCPLYTSPRTVTQAPPKSTADVSTPDSEINLTNVTDIIRVPVFN), which corresponds to amino acids 31 to 205 of SEQ ID NO:1.
[0065] In another embodiment, sTREM-1 comprises the amino acid sequence set forth in SEQ ID NO: 19 (LKEGQTLDVKCDYTLEKFASSQKAWQIIRDGEMPKTLACTERPSKNSHPVQVGRIILEDYHDHGLLRVRMVNLQVEDSGLYQCVIYQPPKEPHMLFDRIRLVVTKGF), which corresponds to amino acids 31 to 137 of SEQ ID NO: 1 and has a length of 200 or less amino acids, preferably 185 or less amino acids.
[0066] In another embodiment, sTREM-1 has the amino acid sequence set forth in SEQ ID NO: 2, SEQ ID NO: 5, or SEQ ID NO: 6. In another embodiment, sTREM-1 has the amino acid sequence set forth in SEQ ID NO: 5 or SEQ ID NO: 6.
[0067] In one embodiment, sTREM-1 is a variant of SEQ ID NO: 2, a variant of SEQ ID NO: 5, or a variant of SEQ ID NO: 6. In one embodiment, sTREM-1 is a variant of SEQ ID NO: 5 or a variant of SEQ ID NO: 6.
[0068] In one embodiment, a variant of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 is an amino acid sequence that comprises at least 25 consecutive amino acids, preferably at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 165, 170, 175, 180 or 185 consecutive amino acids of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6, respectively.
[0069] In another embodiment, the variant of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 is an amino acid sequence comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6, respectively, and additional amino acids at the C-terminus or N-terminus of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6, wherein the number of additional amino acids is in the range of 1 to 50, preferably 1 to 20, more preferably 1 to 10 amino acids, such as 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids at the C-terminus and / or 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids at the N-terminus.
[0070] In another embodiment, a variant of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 is an amino acid sequence that typically differs from the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 by one or more amino acid substitutions, deletions, additions and / or insertions. In one embodiment, the substitution(s), deletion(s), addition(s) and / or insertion(s) may affect 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids.
[0071] In another embodiment, a variant of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 is an amino acid sequence of at least 25 amino acids, preferably at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 165, 170, 175, 180 or 185 amino acids, having at least 60%, 65%, 70%, 75%, 80%, 90%, 95%, or at least 96%, 97%, 98%, 99% or more identity to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6, respectively.
[0072] The terms "identical" or "identity," when used in the context of two or more polypeptide sequences, refer to the degree of sequence relatedness between the polypeptides, as determined by the number of matches between two or more strings of amino acid residues. "Identity" measures the percentage of identical matches between two or more smaller sequences with gap alignments (if any) that are processed by a particular mathematical model or computer program (i.e., an "algorithm"). The identity of related polypeptides can be readily calculated by known methods. Such methods include, but are not limited to, those described in: Computational Molecular Biology, Lesk, AM, ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, DW, ed., Academic Press, New York, 1993; Computer Analysis of Sequence Data, Part 1, Griffin, AM, and Griffin, HG, eds., Humana Press, New Jersey, 1994; Sequence Analysis in Molecular Biology, von Heinje, G., Academic Press, 1987; Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M. Stockton Press, New York, 1991; and Carillo et al., SIAM J. Applied Math. 48, 1073 (1988). Preferred methods for determining identity are designed to give the largest match between the sequences tested. Methods to determine identity are described in publicly available computer programs.Preferred computer program methods for determining identity between two sequences include the GCG program package, such as: GAP (Devereux et al., Nucl. Acid. Res.\2,387 (1984); Genetics Computer Group, University of Wisconsin, Madison, Wis.), BLASTP, BLASTN, and FASTA (Altschul et al., J. MoI. Biol. 215, 403-410 (1990)). The BLASTX program is publicly available from the National Center for Biotechnology Information (NCBI) and other sources (BLAST Manual, Altschul et al., NCB / NLM / NIH Bethesda, Md. 20894; Altschul et al., supra). Identity can also be determined using the well-known Smith Waterman algorithm.
[0073] In one embodiment, the variant of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 is not SEQ ID NO:1.
[0074] In one embodiment, sTREM-1 is a fragment of SEQ ID NO: 2, a fragment of SEQ ID NO: 5, or a fragment of SEQ ID NO: 6. In one embodiment, sTREM-1 is a fragment of SEQ ID NO: 5 or a fragment of SEQ ID NO: 6.
[0075] In one embodiment, a fragment of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6 is an amino acid sequence comprising at least 25 consecutive amino acids, preferably at least 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 165, 170, 175, 180 or 185 consecutive amino acids of the amino acid sequence of SEQ ID NO:2, SEQ ID NO:5 or SEQ ID NO:6, respectively.
[0076] In one embodiment, sTREM-1 corresponds to an extracellular fragment generated by cleavage of membrane-bound TREM-1 having the amino acid sequence set forth in SEQ ID NO:1 by a protease, preferably a matrix metallopeptidase, more preferably matrix metalloproteinase 9 (MMP9).
[0077] As used herein, "biological sample" refers to a biological sample isolated from a human subject, which may include, by way of example and without limitation, a body fluid, a cell sample, and / or a tissue extract, such as a homogenate or solubilized tissue obtained from a human subject.
[0078] In one embodiment, the method of the present invention does not include obtaining a biological sample from a subject. In one embodiment, the biological sample from a human subject is a biological sample previously obtained from a human subject. The biological sample may be stored under appropriate conditions before being used in the method of the present invention.
[0079] In one embodiment, the biological sample from a human subject is a body fluid sample. Examples of body fluids include, but are not limited to, blood, plasma, serum, lymph, urine, bronchoalveolar lavage fluid, cerebrospinal fluid, sweat, or any other body fluid or derivative thereof.
[0080] As used herein, "blood" includes whole blood, plasma, serum, circulating epithelial cells, components, or any other derivative of blood.
[0081] In one embodiment, the biological sample from the human subject is a blood sample. In one embodiment, the biological sample from the human subject is a whole blood sample or a plasma sample. Methods for obtaining plasma samples are routinely used in clinical laboratories. In one embodiment, the whole blood sample or plasma sample from the human subject is processed to obtain a serum sample. Methods for obtaining serum samples from whole blood samples or plasma samples are routinely used in clinical laboratories.
[0082] In another embodiment, the biological sample from a human subject is a tissue extract. Tissue extracts are routinely obtained from tissue biopsy and autopsy material.
[0083] According to the present invention, the term "level" as used herein refers to the expression level of sTREM-1. Alternatively, it can refer to the transcription level of sTREM-1 or the translation level of sTREM-1. The expression level can be detected intracellularly or extracellularly.
[0084] The levels of TREM-1 may be measured in a point-of-care (POCT) or bedside test, a test performed near the patient, or in a central laboratory assay.
[0085] Methods for measuring expression levels, such as transcription or translation levels, are well known to the skilled artisan and include, but are not limited to, RT-PCR, RT-qPCR, Northern blot, hybridization techniques, such as the use of, for example, microarrays, and combinations thereof, such as, for example, hybridization of amplicons obtained by RT-PCR, sequencing, such as, for example, next generation DNA sequencing (NGS) or RNA-seq (also known as "whole transcriptome shotgun sequencing"), immunohistochemistry, multiplex methods (such as Luminex), Western blot, enzyme-linked immunosorbent assay (ELISA), sandwich ELISA, multiplex ELISA, electrochemiluminescence (ECL), also called electrochemiluminescence immunoassay (ECLIA) (such as Elecsys®, Roche). Diagnostics), Enzyme-Linked Fluorescence Assay (ELFA) (such as VIDAS®, Biomerieux), Fluorescence-Linked Immunosorbent Assay (FLISA), Enzyme-Linked Immunosorbent Assay (EIA), Radioimmunoassay (RIA), Flow Cytometry (FACS), Surface Plasmon Resonance (SPR), Biolayer Interferometry (BLI), Immunochromatography Assay (ICA) (such as NEXUS IB10, Sphingotech) and Mass Spectrometry-Based Approaches.
[0086] According to one embodiment, the term "level" as used herein refers to the quantity, amount, or concentration of sTREM-1. Thus, the level of sTREM-1 measured in a biological sample from a human subject refers to the quantity, amount, or concentration of sTREM-1 in the biological sample.
[0087] According to one embodiment, the level of sTREM-1 refers to protein level, protein quantity, protein amount, or protein concentration.
[0088] In one embodiment, the level of sTREM-1 refers to the level of the amino acid sequence set forth in SEQ ID NO:2, SEQ ID NO:5 and / or SEQ ID NO:6, and / or fragments and / or variants thereof as described above. In one embodiment, the level of sTREM-1 refers to the level of the amino acid sequence set forth in SEQ ID NO:5 and / or SEQ ID NO:6, and / or fragments and / or variants thereof as described above.
[0089] In one embodiment, the biological sample from the human subject is a blood sample, and the level of sTREM-1 measured in the biological sample corresponds to the blood concentration of sTREM-1 in the human subject.
[0090] In one embodiment, the biological sample from the human subject is a plasma sample, and the level of sTREM-1 measured in the biological sample corresponds to the plasma concentration of sTREM-1 in the human subject.
[0091] In one embodiment, the biological sample from the human subject is a serum sample, and the level of sTREM-1 measured in the biological sample corresponds to the serum concentration of sTREM-1 in the human subject.
[0092] According to the present invention, the level of sTREM-1 may be measured by any method known in the art.
[0093] Methods for measuring levels of sTREM-1, particularly sTREM-1 protein levels, in biological samples as described above are well known to those skilled in the art and include, but are not limited to, immunohistochemistry, multiplex methods (such as Luminex), Western blot, enzyme-linked immunosorbent assay (ELISA), sandwich ELISA, multiplex ELISA, electrochemiluminescence immunoassay (ECLIA) (such as Elecsys®, Roche Diagnostics), enzyme-linked fluorescence assay (ELFA) (such as VIDAS®, Biomerieux), fluorescence-linked immunosorbent assay (FLISA), enzyme-linked immunosorbent assay (EIA), radioimmunoassay (RIA), flow cytometry (FACS) surface plasmon resonance (SPR), biolayer interferometry (BLI), immunochromatographic assay (ICA) (such as NEXUS IB10, Sphingotech) and mass spectrometry-based approaches.
[0094] Typically, measuring the level of sTREM-1 in a biological sample as described above may include contacting the biological sample with a binding partner capable of selectively interacting with sTREM-1 in the biological sample. In one embodiment, the binding partner is an antibody, such as, for example, a monoclonal antibody or an aptamer.
[0095] In one embodiment, measuring the level of sTREM-1 in a biological sample as described above involves the use of an antibody, such as a polyclonal or monoclonal antibody.
[0096] Examples of antibodies that allow the detection of sTREM-1 include, but are not limited to, a polyclonal antibody raised against the Met1-Arg200 amino acids of human TREM-1 (reference AF1278, R&D Systems), a monoclonal antibody raised against the Ala21-Asn205 amino acids of human TREM-1 (reference MAB1278, R&D Systems), a purified anti-human CD354 (TREM-1) antibody (clone TREM-26, reference 314902, BioLegend), a purified anti-human CD354 (TREM-1) antibody (clone TREM-37, reference 316102, BioLegend), a monoclonal mouse anti-human sTREM1 (clone 15G7, reference 298099, USBio), a mouse anti-human TREM1 (clone 2E2, reference 134704, USBio). Other non-limiting examples of antibodies that allow for the detection of sTREM-1 include sTREM-1 and / or TREM-1 antibodies described in the following patents or patent applications: US 2013 / 150559, US 2013 / 211050, US 2013 / 309239, WO 2013 / 120553 and US 8,106,165.
[0097] Some of the aforementioned assays for measuring the level of sTREM-1 in biological samples (such as Western blot, ELISA, or sandwich ELISA) generally involve binding of a partner (i.e., antibody or aptamer) to a solid support. Solid supports that can be used in the practice of the methods of the present invention include, but are not limited to, supports such as nitrocellulose (e.g., nitrocellulose membrane or nitrocellulose microtiter plate), polyvinyl chloride (e.g., polyvinyl chloride sheet, polyvinyl chloride membrane or polyvinyl chloride microtiter plate), polystyrene latex (e.g., polystyrene latex bead or polystyrene latex microtiter plate), polyvinylidene difluoride or PVDF (e.g., PVDF membrane), diazotized paper, nylon membrane, activated beads, and magnetically responsive beads.
[0098] The level of sTREM-1 may be measured using standard immunodiagnostic techniques, such as immunoassays, such as competitive, direct reaction, or sandwich-type assays. Such assays include, but are not limited to, agglutination tests, enzyme-labeled and mediated immunoassays, such as ELISA, biotin / avidin-type assays, radioimmunoassays, immunoelectrophoresis, and immunoprecipitation. Thus, immunoassays include, but are not limited to, enzyme-labeled and mediated immunoassays, such as ELISA or enzyme-linked fluorescent assay (ELFA), biotin / avidin-type assays, radioimmunoassays, immunoelectrophoresis, immunoprecipitation, and electrochemiluminescence immunoassays (ECLIA).
[0099] An exemplary biochemical test for identifying a particular protein uses a standardized test format such as an ELISA test, but the information provided herein can be applied to the development of other biochemical tests, including but not limited to the development of an ELISA test (see, for example, Molecular Immunology: A Textbook, edited by Atassi et al., Marcel Dekker Inc., New York and Basel 1984, for a description of the ELISA test). It is understood that commercially available assay enzyme-linked immunosorbent assay (ELISA) kits for various plasma components are available.
[0100] Thus, an ELISA method can be used to measure the level of sTREM-1 in a biological sample, in which the wells of a microtiter plate are coated with at least one antibody that recognizes sTREM-1. A biological sample containing or suspected of containing sTREM-1 is then added to the coated wells. After an incubation period sufficient to allow the formation of an antibody-sTREM-1 complex, the plate(s) can be washed to remove unbound moieties and a detectably labeled secondary binding molecule can be added. The secondary binding molecule can react with any captured antibody-sTREM-1 complex, the plate is washed and the presence of the secondary binding molecule is detected using methods well known in the art.
[0101] In one embodiment, measuring the level of sTREM-1 in a biological sample as described above includes using an enzyme-linked immunosorbent assay (ELISA), an electrochemiluminescence immunoassay (ECLIA) (such as Elecsys® Roche Diagnostics) or an enzyme-linked fluorescent assay (ELFA).
[0102] Examples of ELISA assays include, but are not limited to, the TREM-1 Quantikine ELISA Kit (reference DTRM10C, R&D Systems), human TREM-1 DuoSet (references DY1278B and DY1278BE, R&D Systems), sTREM-1 ELISA (reference sTREM-1 ELISA, iQProducts).
[0103] An example of an electrochemiluminescence immunoassay (ECLIA) is Elecsys® (Roche Diagnostics).
[0104] An example of an enzyme-linked fluorescence assay (ELFA) is VIDAS® (Biomerieux).
[0105] Typically, the level of sTREM-1 in a biological sample may be measured by an immunometric assay based on the double antibody "sandwich" technique using a monoclonal antibody specific for sTREM-1. Thus, in one embodiment, measuring the level of sTREM-1 in a biological sample as described above comprises using a sandwich ELISA.
[0106] According to one embodiment, measuring the levels of sTREM-1 (with or without immunoassay-based methods) may also include separation of compounds present in a biological sample (i.e., separation of sTREM-1), centrifugation based on the molecular weight of the compounds, electrophoresis based on mass and charge, HPLC based on hydrophobicity, size exclusion chromatography based on size, and solid phase affinity based on the affinity of the compounds for the particular solid phase used.
[0107] Once separated, the compound (i.e., sTREM-1) can be identified based on the compound's known "separation profile," e.g., retention time, and measured using standard techniques. Alternatively, the separated compound (i.e., sTREM-1) can be detected and measured, for example, by mass spectrometry.
[0108] According to one embodiment, the level of sTREM-1 refers to the nucleic acid level, the nucleic acid quantity, the nucleic acid amount or the nucleic acid concentration. In one embodiment, the nucleic acid is RNA, preferably mRNA, or cDNA.
[0109] Methods for measuring expression levels, in particular sTREM-1 nucleic acid levels, in biological samples as described above are well known to those skilled in the art and include, but are not limited to, PCR, qPCR, RT-PCR, RT-qPCR, Northern blot, hybridization techniques such as the use of, for example, microarrays, and combinations thereof, such as, but not limited to, hybridization of amplicons obtained by RT-PCR, sequencing such as, for example, next generation DNA sequencing (NGS), or RNA-seq (also known as "whole transcriptome shotgun sequencing").
[0110] In one embodiment, sTREM-1 nucleic acid levels are measured using forward and reverse primers having the nucleotide sequences set forth in SEQ ID NO: 13 (GTGGTGACCAAGGGGTTC) and SEQ ID NO: 14 (AGATGGATGTGGCTGGAAGT), respectively.
[0111] In one embodiment, sTREM-1 nucleic acid levels are measured using forward and reverse primers having the nucleotide sequences set forth in SEQ ID NO: 15 (GTGACCAAGGGTTTTTCAGG) and SEQ ID NO: 16 (ACACCGGAACCCTGATGATA), respectively.
[0112] In one embodiment, sTREM-1 nucleic acid levels are measured using forward and reverse primers having the nucleotide sequences set forth in SEQ ID NO: 17 (AAAGGCAAGAACGCCTGAC) and SEQ ID NO: 18 (GGGACTTTACCAAGAGGGAC), respectively.
[0113] In one embodiment, the level of sTREM-1 measured in the biological sample as described above is a baseline level, in other words, the level of sTREM-1 is measured in such a biological sample obtained from a human subject suffering from an inflammatory disorder before the start of a treatment, preferably the administration of a TREM-1 inhibitor.
[0114] In one embodiment, the level of sTREM-1 is measured in said biological sample obtained from the human subject between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours after the onset of an inflammatory disorder, preferably SIRS, sepsis or septic shock, after diagnosis of the human subject with an inflammatory disorder, preferably SIRS, sepsis or septic shock, after hospitalization of the human subject for an inflammatory disorder, preferably SIRS, sepsis or septic shock, in particular admission to an ICU or emergency room, or after initiation of vasopressor therapy.
[0115] In one embodiment, the level of sTREM-1 is measured in the above-mentioned biological sample obtained from the human subject within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 or 48 hours after the onset of an inflammatory disorder, preferably SIRS, sepsis or septic shock, after diagnosis of a human subject with an inflammatory disorder, preferably SIRS, sepsis or septic shock, after hospitalization of a human subject for an inflammatory disorder, preferably SIRS, sepsis or septic shock, in particular admission to an ICU or emergency room, or after the initiation of vasopressor therapy.
[0116] In one embodiment, the level of sTREM-1 is measured in said biological sample between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours after the onset of an inflammatory disorder, preferably SIRS, sepsis or septic shock, after diagnosis of a human subject with an inflammatory disorder, preferably SIRS, sepsis or septic shock, after hospitalization of a human subject for an inflammatory disorder, preferably SIRS, sepsis or septic shock, in particular admission to an ICU or emergency room, or after initiation of vasopressor therapy.
[0117] In one embodiment, the level of sTREM-1 is measured in said biological sample within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42 or 48 hours after the onset of an inflammatory disorder, preferably SIRS, sepsis or septic shock, after diagnosis of a human subject with an inflammatory disorder, preferably SIRS, sepsis or septic shock, after hospitalization of a human subject for an inflammatory disorder, preferably SIRS, sepsis or septic shock, in particular admission to an ICU or emergency room, or after the initiation of vasopressor therapy.
[0118] In one embodiment, the level of sTREM-1 is measured in the above biological sample obtained from a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours after reinfection of the human subject.
[0119] In one embodiment, the level of sTREM-1 is measured in the above biological sample obtained from a human subject within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, or 48 hours after reinfection of the human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0120] In one embodiment, the level of sTREM-1 is measured in the above biological sample between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours after reinfection of a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0121] In one embodiment, the level of sTREM-1 is measured in the above biological sample within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, or 48 hours after reinfection of a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0122] In one embodiment, the level of sTREM-1 is measured in the above-mentioned biological sample obtained from a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours after readmission of the human subject, in particular after readmission to an ICU or emergency room.
[0123] In one embodiment, the level of sTREM-1 is measured in the above biological sample obtained from a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, or 48 hours after readmission of the human subject, in particular after readmission to an ICU or emergency room.
[0124] In one embodiment, the level of sTREM-1 is measured in said biological sample between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours after readmission of a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, in particular after readmission to an ICU or emergency room.
[0125] In one embodiment, the level of sTREM-1 is measured in the above biological sample within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, or 48 hours after readmission of a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, in particular after readmission to an ICU or emergency room.
[0126] In one embodiment, the level of sTREM-1 is measured in the above-mentioned biological sample obtained from the human subject between the first 2 hours and the first 48 hours, preferably between the first 2 hours and the first 12 hours, between the first 12 hours and the first 24 hours, or between the first 24 hours and the first 48 hours, after the onset of septic shock, after the diagnosis of the human subject with septic shock, after the hospitalization of the human subject for septic shock, in particular after admission to an ICU or emergency room, or after the initiation of vasopressor therapy.
[0127] In one embodiment, the level of sTREM-1 is measured in the above biological sample obtained from a human subject within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, or 48 hours after the onset of septic shock, after diagnosis of the human subject with septic shock, after hospitalization of the human subject for septic shock, in particular admission to an ICU or emergency room, or after the initiation of vasopressor therapy.
[0128] In one embodiment, the level of sTREM-1 is measured in the above biological sample between the first 2 hours to the first 12 hours, between the first 12 hours to the first 24 hours, or between the first 24 hours to the first 48 hours after the onset of septic shock, after diagnosis of a human subject with septic shock, after hospitalization of a human subject for septic shock, in particular after admission to an ICU or emergency room, or after initiation of vasopressor therapy.
[0129] In one embodiment, the level of sTREM-1 is measured in the above biological sample within the first 2, 3, 6, 9, 12, 15, 18, 21, 24, 30, 36, 42, or 48 hours after the onset of septic shock, after diagnosis of a human subject with septic shock, after hospitalization of a human subject for septic shock, in particular admission to an ICU or emergency room, or after the initiation of vasopressor therapy.
[0130] In one embodiment, the pre-determined sTREM-1 value is a personalized reference value, ie, the pre-determined sTREM-1 value is obtained using a biological sample obtained from a human subject.
[0131] In one embodiment, the pre-determined value of sTREM-1 is an index value or is derived from one or more risk prediction algorithms or calculated indices of an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0132] In one embodiment, the predetermined value of sTREM-1 is obtained from a reference population.
[0133] According to the present invention, a predetermined sTREM-1 value may be derived from a population study, such as, for example, of subjects having a similar age range, of subjects within the same or similar ethnic group, of subjects with a chronic medical condition associated with an increased risk of inflammatory disorders, preferably SIRS, sepsis or septic shock (such as atrial fibrillation, cancer, chronic kidney disease, chronic lung disease, liver cirrhosis, coronary artery disease, deep vein thrombosis, diabetes, dyslipidemia, endocarditis, hypertension, influenza, malaria, or other protozoan parasitic diseases, myocardial infarction, neurological diseases, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), peripheral arterial disease, pulmonary fibrosis, severe obesity and stroke) or a history of an inflammatory disorder such as SIRS, sepsis, septic shock.
[0134] According to one embodiment, the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more substantially healthy human subjects. As used herein, a "substantially healthy subject" is a human subject that has not been previously diagnosed or identified as having or suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock. Thus, according to one embodiment, the predetermined sTREM-1 value is obtained from a reference population of substantially healthy human subjects.
[0135] In one embodiment, a "substantially healthy subject" is a human subject that is not suffering from an infectious disease.
[0136] According to one embodiment, the predetermined value for sTREM-1 obtained from a reference population of substantially healthy human subjects is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 50 pg / mL to about 250 pg / mL.
[0137] In one embodiment, the predetermined value for sTREM-1 obtained from a reference population of substantially healthy human subjects is a sTREM-1 level, preferably a blood, plasma or serum level, of about 50 pg / mL, 75 pg / mL, 100 pg / mL, 125 pg / mL, 150 pg / mL, 175 pg / mL, 200 pg / mL, 225 pg / mL, or 250 pg / mL.
[0138] In one embodiment, the predetermined value for sTREM-1 obtained from a reference population of substantially healthy human subjects is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 50 pg / mL to about 150 pg / mL, particularly as determined using an enzyme-linked immunosorbent assay (ELISA).
[0139] In one embodiment, the predetermined value for sTREM-1 obtained from a reference population of substantially healthy human subjects is a sTREM-1 level, preferably a blood, plasma or serum level, of about 50 pg / mL, 75 pg / mL, 100 pg / mL, 125 pg / mL or 150 pg / mL, particularly as determined using an enzyme-linked immunosorbent assay (ELISA).
[0140] In one embodiment, the predetermined value for sTREM-1 obtained from a reference population of substantially healthy human subjects is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 150 pg / mL to about 250 pg / mL, particularly as determined using an electrochemiluminescence immunoassay (ECLIA).
[0141] In one embodiment, the predetermined value for sTREM-1 obtained from a reference population of substantially healthy human subjects is a sTREM-1 level, preferably a blood, plasma or serum level, of about 150 pg / mL, 175 pg / mL, 200 pg / mL, 225 pg / mL, or 250 pg / mL, particularly as determined using an electrochemiluminescence immunoassay (ECLIA).
[0142] According to another embodiment, the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects diagnosed or identified as suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock. Thus, according to one embodiment, the predetermined sTREM-1 value is obtained from a reference population of human subjects diagnosed or identified as suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0143] In one embodiment, the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects diagnosed or identified as having sepsis. Thus, in one embodiment, the predetermined sTREM-1 value is obtained from a reference population of human subjects diagnosed or identified as having sepsis.
[0144] In one embodiment, the in vitro method of the invention is for identifying a human subject suffering from sepsis who is likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor, and the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects diagnosed or identified as suffering from sepsis. In other words, in one embodiment, the in vitro method of the invention is for identifying a human subject suffering from sepsis who is likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor, and the predetermined value of sTREM-1 is obtained from a reference population of human subjects diagnosed or identified as suffering from sepsis.
[0145] In one embodiment, the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects diagnosed or identified as suffering from septic shock. Thus, in one embodiment, the predetermined sTREM-1 value is obtained from a reference population of human subjects diagnosed or identified as suffering from septic shock.
[0146] In one embodiment, the in vitro method of the invention is for identifying a human subject suffering from septic shock who is likely to respond to a therapy, in particular to the administration of a TREM-1 inhibitor, and the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects diagnosed or identified as suffering from septic shock. In other words, in one embodiment, the in vitro method of the invention is for identifying a human subject suffering from septic shock who is likely to respond to a therapy, in particular to the administration of a TREM-1 inhibitor, and the predetermined value of sTREM-1 is obtained from a reference population of human subjects diagnosed or identified as suffering from septic shock.
[0147] In one embodiment, the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects previously diagnosed or identified as suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0148] In one embodiment, the predetermined value of sTREM-1 is derived from measurements of sTREM-1 levels in biological samples from one or more human subjects suffering from an inflammatory disorder, preferably an infection at high risk of developing SIRS, sepsis or septic shock.
[0149] According to the present invention, the predetermined sTREM-1 value can be derived from statistical analysis and / or risk prediction data of the above-mentioned reference populations obtained from mathematical algorithms and calculated indices of inflammatory disorders, preferably SIRS, sepsis or septic shock.
[0150] According to one embodiment, the pre-determined value of sTREM-1 is obtained from a reference population, as described above, using statistical and / or structural classification methods.
[0151] According to one embodiment, the predetermined sTREM-1 value, preferably obtained from a reference population as described above, is a sTREM-1 level, preferably a blood, plasma or serum level.
[0152] In one embodiment, a human subject suffering from an inflammatory disorder that is amenable to treatment is a human subject having a level of sTREM-1 measured as described above that is at least 1.5-fold, 2-fold, 2.5-fold, 3-fold, 3.5-fold, 4-fold, 4.5-fold, 5-fold, 5.5-fold, 6-fold, 6.5-fold, 7-fold, 7.5-fold, 8-fold, 8.5-fold, 9-fold, 9.5-fold, or 10-fold higher than a given sTREM-1, preferably a given sTREM-1 obtained from a reference population of substantially healthy human subjects as described above.
[0153] In one embodiment, a human subject suffering from an inflammatory disorder amenable to treatment is a human subject having a level of sTREM-1 measured as described above that is at least 1.6-fold, 1.8-fold, 2-fold, 2.2-fold, 2.4-fold, 2.6-fold, 2.8-fold, 3-fold, 3.2-fold, 3.4-fold, 3.6-fold, 3.8-fold, 4-fold, 4.2-fold, 4.4-fold, 4.6-fold, 4.8-fold, 5-fold, 5.2-fold, 5.4-fold, 5.6-fold, 5.8-fold, or 6-fold higher than a given sTREM-1, preferably a given sTREM-1 obtained from a reference population of substantially healthy human subjects as described above.
[0154] In one embodiment, a human subject suffering from an inflammatory disorder amenable to treatment is a human subject having a level of sTREM-1 measured as described above that is at least 2-fold, 2.1-fold, 2.2-fold, 2.3-fold, 2.4-fold, 2.5-fold, 2.6-fold, 2.7-fold, 2.8-fold, 2.9-fold, 3-fold, 3.1-fold, 3.2-fold, 3.3-fold, 3.4-fold, 3.5-fold, 3.6-fold, 3.7-fold, 3.8-fold, 3.9-fold, or 4-fold higher than a given sTREM-1, preferably a given sTREM-1 obtained from a reference population of substantially healthy human subjects as described above.
[0155] In another embodiment, a human subject suffering from an inflammatory disorder susceptible to a treatment is a human subject having a level of a given sTREM-1, preferably sTREM-1, measured as described above, that is at least 1.1-fold, 1.2-fold, 1.3-fold, 1.4-fold, 1.5-fold, 1.6-fold, 1.7-fold, 1.8-fold, 1.9-fold, 2-fold, 2.1-fold, 2.2-fold, 2.3-fold, 2.4-fold or 2.5-fold higher than a given sTREM-1 obtained from a reference population of human subjects diagnosed or identified as suffering from, or suffering from, an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0156] In one embodiment, the predetermined sTREM-1 value obtained from said reference population is the mean sTREM-1 level of the reference population, preferably the mean blood, plasma or serum level. In another embodiment, the predetermined sTREM-1 value obtained from said reference population is the median sTREM-1 level of the reference population, preferably the mean blood, plasma or serum level.
[0157] According to one embodiment, a predetermined sTREM-1 value is obtained from the above-mentioned reference population, and the sTREM-1 levels measured in each biological sample of the human subjects of the reference population (i.e., the sTREM-1 levels measured in the reference population) are divided into groups of equal size by cut-off values called "quantiles", each group corresponding to a predetermined proportion (percentage) of the sTREM-1 levels measured in the reference population. Examples of quantiles include, but are not limited to, median (defining two groups, each group containing 50% of the sTREM-1 levels measured in a reference population), terciles or tertiles (defining three groups, each group containing one-third of the sTREM-1 levels measured in a reference population), quartiles (defining four groups, each group containing 25% of the sTREM-1 levels measured in a reference population), quintiles (defining five groups, each group containing 20% of the sTREM-1 levels measured in a reference population), and deciles (defining ten groups, each group containing 10% of the sTREM-1 levels measured in a reference population).
[0158] According to the present invention, "quantile" refers to a cut-off sTREM-1 value, above and below which there is a certain percentage of the sTREM-1 levels measured in a reference population.Therefore, the human subject with a measured sTREM-1 level below the first quantile is the human subject with the lowest sTREM-1 level, and the human subject with a measured sTREM-1 level above the last quantile is the human subject with the highest sTREM-1 level.For example, the first decile is the sTREM-1 value below which 10% of the sTREM-1 levels measured in the reference population are below and above which 90% of the sTREM-1 levels measured in the reference population are above.
[0159] Furthermore, the term "quantile" may refer to a group so defined by a cut-off value. Thus, as applied to the present invention, the term "quantile" may refer to a group of sTREM-1 levels measured in a reference population defined by a cut-off sTREM-1 value. For example, the first decile may refer to a group of sTREM-1 levels measured in a reference population that corresponds to the lowest 10% of sTREM-1 levels measured in the reference population. Thus, the tenth decile refers to a group of sTREM-1 levels measured in a reference population that corresponds to the highest 10% of sTREM-1 levels measured in the reference population. Thus, the sTREM-1 values in the first decile are those that fall within the lowest 10% of sTREM-1 levels measured in the reference population, and the sTREM-1 values in the tenth decile are those that fall within the highest 10% of sTREM-1 levels measured in the reference population.
[0160] In one embodiment, the predetermined sTREM-1 values are obtained from a reference population as described above, and the sTREM-1 levels measured in the reference population are divided into two equally sized groups, each corresponding to 50% of the sTREM-1 levels measured in the reference population.
[0161] According to this embodiment of the invention, the median sTREM-1 value corresponds to the sTREM-1 value below which 50% of the sTREM-1 levels measured in a reference population fall and above which 50% of the sTREM-1 levels measured in a reference population fall.
[0162] Thus, in one embodiment, the predetermined sTREM-1 value is the median sTREM-1 value for a reference population, as set forth above.
[0163] Thus, in one embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to a therapy, in particular to the administration of a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value obtained from a reference population sTREM-1, the predetermined sTREM-1 value being the median value of the reference population; and c) identifying human subjects suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having sTREM-1 levels measured in step a) that are higher than the median value in step b) as likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor.
[0164] In one embodiment, the predetermined sTREM-1 value is obtained from a reference population as described above, and the sTREM-1 levels measured in the reference population are divided into three equal-sized groups, each corresponding to one-third of the sTREM-1 levels measured in the reference population. As described above, the cutoff values ("quantiles") are called "terciles" (or "tertiles") because they divide the sTREM-1 levels measured in the reference population. Thus, in one embodiment, the predetermined sTREM-1 value is the sTREM-1 tercile (or tertile) of the reference population, as described above.
[0165] According to this embodiment of the invention: - the first tercile (or tertile) of sTREM-1 corresponds to an sTREM-1 value below which one-third of the sTREM-1 levels measured in the reference population are located and above which two-thirds of the sTREM-1 levels measured in the reference population are located; and - The second tercile (or tertile) of sTREM-1 corresponds to the sTREM-1 value below which two-thirds of the sTREM-1 levels measured in the reference population lie and above which one-third of the sTREM-1 levels measured in the reference population lie.
[0166] In one embodiment, the predetermined sTREM-1 value is the second sTREM-1 tertile (ie, the last sTREM-1 tertile) of a reference population, as described above.
[0167] In one embodiment, the predetermined sTREM-1 value is obtained from a reference population as described above, and the sTREM-1 levels measured in the reference population are divided into four equal-sized groups, each corresponding to 25% of the sTREM-1 levels measured in the reference population. As described above, the cutoff values ("quantiles") are called "quartiles" because they divide the sTREM-1 levels measured in the reference population. Thus, in one embodiment, the predetermined sTREM-1 value is the sTREM-1 quartile of the reference population, as described above.
[0168] According to this embodiment of the invention: - the first quartile (or Q1) of sTREM-1 corresponds to the sTREM-1 value below which 25% of the sTREM-1 levels measured in the reference population lie and above which 75% of the sTREM-1 levels measured in the reference population lie, - the second quartile of sTREM-1 corresponds to the sTREM-1 value below which 50% of the sTREM-1 levels measured in the reference population lie and above which 50% of the sTREM-1 levels measured in the reference population lie (the second quartile is therefore equivalent to the median); - The third quartile (or Q3) of sTREM-1 corresponds to the sTREM-1 value below which 75% of the sTREM-1 levels measured in the reference population lie and above which 25% of the sTREM-1 levels measured in the reference population lie.
[0169] In one embodiment, the predetermined sTREM-1 value is the first sTREM-1 quartile, also referred to as sTREM-1 Q1, of the reference population as described above.
[0170] In one embodiment, the predetermined sTREM-1 value is the third sTREM-1 quartile, also referred to as sTREM-1 Q3 (ie, the last sTREM-1 quartile), of the reference population, as described above.
[0171] Thus, in one embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to a therapy, in particular to the administration of a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predefined sTREM-1 value obtained from a reference population sTREM-1, the predefined sTREM-1 value being the third quartile of the reference population; and c) identifying human subjects suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having an sTREM-1 level measured in step a) higher than the third quartile of step b) as likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor.
[0172] In one embodiment, the predetermined sTREM-1 value is obtained from a reference population as described above, and the sTREM-1 levels measured in the reference population are divided into five equally sized groups, each corresponding to 20% of the sTREM-1 levels measured in the reference population. As described above, the cut-off values ("quantiles") are called "quintiles" because they divide the sTREM-1 levels measured in the reference population. Thus, in one embodiment, the predetermined sTREM-1 value is the sTREM-1 quintile of the reference population, as shown above.
[0173] According to this embodiment of the invention: - the first quintile of sTREM-1 corresponds to an sTREM-1 value below which 20% of the sTREM-1 levels measured in the reference population lie and above which 80% of the sTREM-1 levels measured in the reference population lie, - the second quintile of sTREM-1 corresponds to an sTREM-1 value below which 40% of the sTREM-1 levels measured in the reference population lie and above which 60% of the sTREM-1 levels measured in the reference population lie, - the third quintile of sTREM-1 corresponds to an sTREM-1 value below which 60% of the sTREM-1 levels measured in the reference population are located and above which 40% of the sTREM-1 levels measured in the reference population are located, and - The fourth quintile of sTREM-1 corresponds to an sTREM-1 value below which 80% of the sTREM-1 levels measured in the reference population lie and above which 20% of the sTREM-1 levels measured in the reference population lie.
[0174] In one embodiment, the predetermined sTREM-1 value is a second sTREM-1 quintile of a reference population, as described above.
[0175] In one embodiment, the predetermined sTREM-1 value is the third sTREM-1 quintile (ie, the penultimate sTREM-1 quintile) of a reference population, as described above.
[0176] In one embodiment, the predetermined sTREM-1 value is the fourth sTREM-1 quintile (ie, the last sTREM-1 quintile) of a reference population, as described above.
[0177] In one embodiment, the predefined sTREM-1 value is obtained from a reference population as described above, and the sTREM-1 levels measured in the reference population are divided into 10 equally sized groups, each corresponding to 10% of the sTREM-1 levels measured in the reference population. As described above, the cut-off values ("quantiles") are called "deciles" because they divide the sTREM-1 levels measured in the reference population. Thus, in one embodiment, the predefined sTREM-1 value is the sTREM-1 decile of the reference population, as described above.
[0178] According to this embodiment of the invention: - a first decile of sTREM-1 corresponds to an sTREM-1 value below which 10% of the sTREM-1 levels measured in the reference population lie and above which 90% of the sTREM-1 levels measured in the reference population lie, a second decile of sTREM-1 corresponds to an sTREM-1 value below which 20% of the sTREM-1 levels measured in the reference population lie and above which 80% of the sTREM-1 levels measured in the reference population lie, - the third decile of sTREM-1 corresponds to an sTREM-1 value below which 30% of the sTREM-1 levels measured in the reference population lie and above which 70% of the sTREM-1 levels measured in the reference population lie, - the fourth decile of sTREM-1 corresponds to an sTREM-1 value below which 40% of the sTREM-1 levels measured in the reference population lie and above which 60% of the sTREM-1 levels measured in the reference population lie, - the fifth decile of sTREM-1 corresponds to an sTREM-1 value below which 50% of the sTREM-1 levels measured in the reference population lie and above which 50% of the sTREM-1 levels measured in the reference population lie, - the sixth decile of sTREM-1 corresponds to an sTREM-1 value below which 60% of the sTREM-1 levels measured in the reference population lie and above which 40% of the sTREM-1 levels measured in the reference population lie, - the seventh decile of sTREM-1 corresponds to an sTREM-1 value below which 70% of the sTREM-1 levels measured in the reference population lie and above which 30% of the sTREM-1 levels measured in the reference population lie, - the 8th decile of sTREM-1 corresponds to a sTREM-1 value below which 80% of the sTREM-1 levels measured in the reference population lie and above which 20% of the sTREM-1 levels measured in the reference population lie, - The 9th decile of sTREM-1 corresponds to the sTREM-1 value below which 90% of the sTREM-1 levels measured in the reference population lie and above which 10% of the sTREM-1 levels measured in the reference population lie.
[0179] In one embodiment, the predetermined sTREM-1 value is the sixth sTREM-1 decile of the reference population, as described above. In one embodiment, the predetermined sTREM-1 value is the seventh sTREM-1 decile of the reference population, as described above. In one embodiment, the predetermined sTREM-1 value is the eighth sTREM-1 decile (i.e., the penultimate sTREM-1 decile) of the reference population, as described above.
[0180] In one embodiment, the predetermined sTREM-1 value is the 9th sTREM-1 decile (ie, the last sTREM-1 decile) of the reference population, as described above.
[0181] In one embodiment, the predefined sTREM-1 value is obtained from a reference population as described above, and the sTREM-1 levels measured in the reference population are divided into groups corresponding to certain percentages of the sTREM-1 levels measured in the reference population. As described above, the cut-off values ("quantiles") are called "percentiles" because they divide the sTREM-1 levels measured in the reference population. Thus, in one embodiment, the predefined sTREM-1 value is the sTREM-1 percentile of the reference population as described above.
[0182] According to one embodiment, the predetermined sTREM-1 value is obtained from a reference population as described above, and the value is associated with a 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% predicted mortality rate in the reference population.
[0183] For example, a given sTREM-1 value associated with a predicted mortality rate of 50% in a reference population means that for subjects in the reference population having sTREM-1 levels higher than this value, the mortality rate is 50%.
[0184] According to one embodiment, the predetermined sTREM-1 value is obtained from a reference population as described above and including patients affected by SIRS, sepsis or septic shock, wherein more than 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95% of subjects in the reference population who die 28, 90 or 365 days after initial infection or initial hospitalization exhibit a value higher than the predetermined sTREM-1 value.
[0185] According to one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 20 pg / mL to about 6000 pg / mL.
[0186] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, is about 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1500, 1600, 1700, 1800, 1900, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 5000, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2100, 2200, 23 0, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 30 50, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4 sTREM-1 levels of 750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5450, 5500, 5550, 5600, 5650, 5700, 5750, 5800, 5850, 5900, 5950 or 6000 pg / mL, preferably blood, plasma or serum levels.
[0187] According to one embodiment, the predetermined sTREM-1 value, preferably obtained from the reference population described above, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 30 pg / mL to about 2000 pg / mL.
[0188] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as above, is an sTREM-1 level, preferably a blood, plasma or serum level, of about 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950 or 2000 pg / mL.
[0189] According to one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 50 pg / mL to about 1000 pg / mL.
[0190] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is about 50, 75, 100, 125, 150, 175, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040, 1050, 1060, 1070, , 440, 450, 460, 470, 480, 490, 500, 520, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940, 960, 980 or 1000 pg / mL sTREM-1 levels, preferably blood, plasma or serum levels.
[0191] According to another embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 250 pg / mL to about 400 pg / mL.
[0192] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, of about 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395 or 400 pg / mL.
[0193] According to another embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 300 pg / mL to about 800 pg / mL.
[0194] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, is about 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, sTREM-1 levels of 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795 or 800 pg / mL, preferably blood, plasma or serum levels.
[0195] According to another embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 350 pg / mL to about 600 pg / mL.
[0196] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, is about 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, sTREM-1 levels of 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595 or 600 pg / mL, preferably blood, plasma or serum levels.
[0197] According to another embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 400 pg / mL to about 500 pg / mL.
[0198] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, of about 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495 or 500 pg / mL.
[0199] According to another embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is a sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 500 pg / mL to about 600 pg / mL.
[0200] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, of about 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595 or 600 pg / mL.
[0201] According to one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, determined by enzyme-linked immunosorbent assay (ELISA).
[0202] As indicated above, examples of ELISA assays include, but are not limited to, the TREM-1 Quantikine ELISA Kit (reference DTRM10C, R&D Systems), human TREM-1 DuoSet (references DY1278B and DY1278BE, R&D Systems), and sTREM-1 ELISA (reference sTREM-1 ELISA, iQProducts).
[0203] In one embodiment, the enzyme-linked immunosorbent assay (ELISA) is the TREM-1 Quantikine ELISA kit (reference DTRM10C, R&D Systems).
[0204] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 50 pg / mL to about 1000 pg / mL when determined using an ELISA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as an electrochemiluminescence immunoassay (ECLIA) or an enzyme-linked fluorescence assay (ELFA).
[0205] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, when determined using ELISA, is about 50, 75, 100, 125, 150, 175, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 520, 540, 560, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 1040, 1050, 1060, 1070, 1080, 1090, 10 sTREM-1 levels, preferably blood, plasma or serum levels, of 0, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940, 960, 980 or 1000 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ECLIA or ELFA.
[0206] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 300 pg / mL to about 800 pg / mL when determined using ELISA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ECLIA or ELFA.
[0207] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, when determined using ELISA, is about 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 406, 407, 408, 409, 410, 411, 412, 413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 430, 435, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 500, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 520, 525, 526, 527, 528, 529, 530, 531, 532, 533, 534, 535, 536, 537, 538, 539, 540, 545, 546, 547, 548, 549, 5, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 58 sTREM-1 levels, preferably blood, plasma or serum levels, of 0, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795 or 800 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, if determined using another immunoassay such as ECLIA or ELFA.
[0208] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 350 pg / mL to about 600 pg / mL when determined using ELISA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ECLIA or ELFA.
[0209] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, is about 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, , 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595 or 600 pg / mL sTREM-1 levels, preferably blood, plasma or serum levels, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ECLIA or ELFA.
[0210] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 400 pg / mL to about 500 pg / mL when determined using ELISA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ECLIA or ELFA.
[0211] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, of about 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495 or 500 pg / mL when determined using ELISA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ECLIA or ELFA.
[0212] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 500 pg / mL to about 600 pg / mL when determined using ELISA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ECLIA or ELFA.
[0213] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, of about 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595 or 600 pg / mL when determined using an enzyme-linked immunosorbent assay (ELISA), or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as an ECLIA or ELFA.
[0214] According to one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, determined by electrochemiluminescence immunoassay (ECLIA).
[0215] As noted above, an example of an electrochemiluminescence immunoassay (ECLIA) is Elecsys® (Roche Diagnostics).
[0216] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 20 pg / mL to about 6000 pg / mL when determined using an electrochemiluminescence immunoassay (ECLIA), or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay, such as an enzyme-linked immunosorbent assay (ELISA) or an enzyme-linked fluorescent assay (ELFA).
[0217] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, when determined using ECLIA, is about 20, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3050, 3100, 3150, 3200, 3250, 3300, 335 0, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4050, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5050, 5100, 5150, 5200, 5250, 5 sTREM-1 levels, preferably blood, plasma or serum levels, of 300, 5350, 5400, 5450, 5500, 5550, 5600, 5650, 5700, 5750, 5800, 5850, 5900, 5950 or 6000 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ELFA.
[0218] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 30 pg / mL to about 3000 pg / mL when determined using ECLIA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ELFA.
[0219] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, is about 30, 50, 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 4000, 4100, 4200, 4300, 4400, 4500, 4600, 4700, 4800, 4900, 5000, 5100, 5200, 5300, 5400, 5500, 5600, 5700, 5800, 5900, 6000, 6100, 6200, 6300, sTREM-1 levels, preferably blood, plasma or serum levels, of 0, 1900, 1950, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950 or 3000 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ELFA.
[0220] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 500 pg / mL to about 1500 pg / mL, preferably about 800 pg / mL to about 1200 pg / mL when determined using ECLIA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ELFA.
[0221] In one embodiment, the predetermined sTREM-1 value, preferably a predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 500 pg / mL to about 600 pg / mL, about 600 pg / mL to about 700 pg / mL, about 700 pg / mL to about 800 pg / mL, about 800 pg / mL to about 900 pg / mL, or about 900 pg / mL to about 1000 pg / mL when determined using ECLIA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ELFA.
[0222] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, when determined using ECLIA, is about 500, 520, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940, 960, 980, 1000, 1020, 1040, 1060, 1080, 1100, 1120, 1140, 1160, 1180, 1200, 1220, 1240, 1260, 1280, 1300, 1320, 1340, 1360, 1380, 1400, 1420, 1440, 1460, 1480 or 1500 pg / mL sTREM-1 levels, preferably blood, plasma or serum levels, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ELFA.
[0223] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 1000 pg / mL to about 2000 pg / mL, preferably about 1200 pg / mL to about 1600 pg / mL when determined using ECLIA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ELFA.
[0224] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, when determined using ECLIA, is between about 1000 pg / mL and about 1100 pg / mL, between about 1100 pg / mL and about 1200 pg / mL, between about 1200 pg / mL and about 1300 pg / mL, between about 1300 pg / mL and about 1400 pg / mL, between about 1400 pg / mL and about 1500 pg / mL, between about 1500 pg / mL and about 1600 pg / mL, between about 1 sTREM-1 levels, preferably blood, plasma or serum levels, in the range of 600 pg / mL to about 1700 pg / mL, about 1700 pg / mL to about 1800 pg / mL, about 1800 pg / mL to about 1900 pg / mL or about 1900 pg / mL to about 2000 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ELFA.
[0225] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, is about 1000, 1020, 1040, 1060, 1080, 1100, 1120, 1140, 1160, 1180, 1200, 1220, 1240, 1260, 1280, 1300, 1320, 1340, 1360, 1380, 1400, 1420, 1440, 1460, 1480, 1500, 1520, 1540, 1560, 1580, 1600, 1700, 1720, 1740, 1760, 1780, 1780, 1790, 1800, 1810, 1820, 1830, 1840, 1850, 1860, 1870, 1880, 1890, 1900, 1910, 1920, 1930, 1940, 1950, 1960, 1970, 1980, 1990, 2000, 2010, 2020, 2030, 2040, 2050, 2060, 2070, 2080, 2090, 3000, 3010, 3020, 3030, 3040, 3050, 3060, 3070, 3080, 3090, 4000, 4 In some embodiments, the sTREM-1 level is 00, 1620, 1640, 1660, 1680, 1700, 1720, 1740, 1760, 1780, 1800, 1820, 1840, 1860, 1880, 1900, 1920, 1940, 1960, 1980 or 2000 pg / mL, preferably a blood, plasma or serum level, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ELFA.
[0226] According to one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, determined by enzyme-linked fluorescence assay (ELFA).
[0227] As noted above, examples of enzyme-linked fluorescent assays (ELFA) include VIDAS® (Biomerieux).
[0228] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 30 pg / mL to about 3000 pg / mL, preferably about 300 pg / mL to about 2000 pg / mL, when determined using an ELFA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay, such as an enzyme-linked immunosorbent assay (ELISA) or an electrochemiluminescence immunoassay (ECLIA).
[0229] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, when determined using ELFA, is about 30, 50, 100, 150, 200, 250, 300, 325, 350, 375, 400, 425, 450, 475, 500, 525, 550, 575, 600, 625, 650, 675, 70 0, 725, 750, 775, 800, 825, 850, 875, 900, 925, 950, 975, 1000, 1025, 1050, 1075, 1100, 1125, 1150, 1175, 1200, 1225, 1250, 1275, 1300, 1325, 1350, 1375, 1400, 1425, 1450, 1475, 1500, 1525, 1 550, 1575, 1600, 1625, 1650, 1675, 1700, 1725, 1750, 1775, 1800, 1825, 1850, 1875, 1900, 1925, 1950, 1975, 2000, 2050, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 265 sTREM-1 levels, preferably blood, plasma or serum levels, of 0, 2700, 2750, 2800, 2850, 2900, 2950 or 3000 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ECLIA.
[0230] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 500 pg / mL to about 1500 pg / mL, preferably about 800 pg / mL to about 1200 pg / mL when determined using ELFA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ECLIA.
[0231] In one embodiment, the predetermined sTREM-1 value, preferably a predetermined sTREM-1 value obtained from a reference population as described above, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 500 pg / mL to about 600 pg / mL, about 600 pg / mL to about 700 pg / mL, about 700 pg / mL to about 800 pg / mL, about 800 pg / mL to about 900 pg / mL, or about 900 pg / mL to about 1000 pg / mL when determined using an ELFA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as an ELISA or ECLIA.
[0232] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, when determined using ELFA, is about 500, 520, 540, 560, 580, 600, 620, 640, 660, 680, 700, 720, 740, 760, 780, 800, 820, 840, 860, 880, 900, 920, 940, 960, 980, 1000, 1020, 1040, 1060, 1080, 1100, 1120, 1140, 1160, 1180, 1190, 1200, 1210, 1220, 1230, 1240, 1250, 1260, 1270, 1280, 1290, 1300, 1310, 1320, 1330, 1340, 1350, 1360, 1370, 1380, 1390, 1400, 1410, 1420, 1430, 1440, 1450, 1460, 1470, 1480, 1490, 1500, 1510, 1520, 1530, 1540, 1550, 1560, 1570, 1580, 1590, 1600, 1610, 1620, 1630, 1640, 1650, 1 160, 1180, 1200, 1220, 1240, 1260, 1280, 1300, 1320, 1340, 1360, 1380, 1400, 1420, 1440, 1460, 1480 or 1500 pg / mL sTREM-1 levels, preferably blood, plasma or serum levels, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ECLIA.
[0233] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the above reference population, is an sTREM-1 level, preferably a blood, plasma or serum level, in the range of about 1000 pg / mL to about 2000 pg / mL, preferably about 1200 pg / mL to about 1600 pg / mL when determined using ELFA, or a corresponding sTREM-1 level, preferably a blood, plasma or serum level, when determined using another immunoassay such as ELISA or ECLIA.
[0234] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population described above, when determined using ELFA, is between about 1000 pg / mL and about 1100 pg / mL, between about 1100 pg / mL and about 1200 pg / mL, between about 1200 pg / mL and about 1300 pg / mL, between about 1300 pg / mL and about 1400 pg / mL, between about 1400 pg / mL and about 1500 pg / mL, between about 1500 pg / mL and about 1600 pg / mL, between about 1600 pg / mL and about 1700 pg / mL, between about 1700 pg / mL and about 1800 pg / mL, between about 1800 pg / mL and about 1900 pg / mL, between about 1900 pg / mL and about 2000 pg / mL, between about 2000 pg / mL and about 2100 pg / mL, between about 2100 pg / mL and about 2200 pg / mL, between about 2200 pg / mL and about 2300 pg / mL, between about 2300 pg / mL and about 2400 pg / mL, between about 2400 pg / mL and about 2500 pg / mL, between about 2500 pg / mL and about 2600 pg / mL, between about 2600 pg / mL and about 2700 pg / mL, between about 2700 pg / mL and about 2800 pg / mL, between about 2800 pg / mL and about 2900 pg / mL, between about 2900 pg / mL and about 3000 pg / mL, between about 3000 pg / mL In one embodiment, the sTREM-1 level, preferably blood, plasma or serum levels, is in the range of about 100 pg / mL to about 1700 pg / mL, about 1700 pg / mL to about 1800 pg / mL, about 1800 pg / mL to about 1900 pg / mL or about 1900 pg / mL to about 2000 pg / mL, or the corresponding sTREM-1 level, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ECLIA.
[0235] In one embodiment, the predetermined sTREM-1 value, preferably the predetermined sTREM-1 value obtained from the reference population as described above, when determined using ELFA, is about 1000, 1020, 1040, 1060, 1080, 1100, 1120, 1140, 1160, 1180, 1200, 1220, 1240, 1260, 1280, 1300, 1320, 1340, 1360, 1380, 1400, 1420, 1440, 1460, 1480, 1500, 1520, 1540, 1560, 1580, 160 sTREM-1 levels, preferably blood, plasma or serum levels, of 0, 1620, 1640, 1660, 1680, 1700, 1720, 1740, 1760, 1780, 1800, 1820, 1840, 1860, 1880, 1900, 1920, 1940, 1960, 1980 or 2000 pg / mL, or the corresponding sTREM-1 levels, preferably blood, plasma or serum levels, when determined using another immunoassay such as ELISA or ECLIA.
[0236] Thus, in one embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to a therapy, in particular to the administration of a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value, preferably obtained from a reference population sTREM-1, the predetermined sTREM-1 value being a blood sTREM-1 level in the range of about 350 pg / mL to about 600 pg / mL; and c) identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having an sTREM-1 level measured in step a) that is higher than the predetermined sTREM-1 value in step b), as likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor.
[0237] In another embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to a therapy, in particular to the administration of a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predefined sTREM-1 value, preferably obtained from a reference population sTREM-1, the predefined sTREM-1 value being a blood sTREM-1 level in the range of about 300 pg / mL to about 800 pg / mL, preferably about 350 pg / mL to about 600 pg / mL, as determined using an enzyme-linked immunosorbent assay (ELISA), or a corresponding blood sTREM-1 level as determined using another immunoassay, such as an ECLIA or ELFA; and c) identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having an sTREM-1 level measured in step a) that is higher than the predetermined sTREM-1 value in step b), as likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor.
[0238] In another embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to a therapy, in particular to the administration of a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predefined sTREM-1 value, preferably obtained from a reference population sTREM-1, the predefined sTREM-1 value being a blood sTREM-1 level in the range of about 20 pg / mL to about 6000 pg / mL, preferably about 30 pg / mL to about 3000 pg / mL, as determined using an electrochemiluminescence immunoassay (ECLIA), or a corresponding blood sTREM-1 level as determined using another immunoassay such as ELISA or ELFA; and c) identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having an sTREM-1 level measured in step a) that is higher than the predetermined sTREM-1 value in step b), as likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor.
[0239] In another embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to a therapy, in particular to the administration of a TREM-1 inhibitor, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with a predefined sTREM-1 value, preferably obtained from a reference population sTREM-1, the predefined sTREM-1 value being a blood sTREM-1 level in the range of about 30 pg / mL to about 3000 pg / mL, preferably about 300 pg / mL to about 2000 pg / mL, as determined using an enzyme-linked fluorescent assay (ELFA), or a corresponding blood sTREM-1 level as determined using another immunoassay, such as an ELISA or ECLIA; and c) identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having an sTREM-1 level measured in step a) that is higher than the predetermined sTREM-1 value in step b), as likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor.
[0240] According to one embodiment, the therapy is an immunomodulatory or anti-inflammatory therapy.
[0241] Examples of immunomodulatory or anti-inflammatory therapies include, but are not limited to, checkpoint inhibitors such as anti-PD-1, anti-PD-L1 and anti-CTLA4, TLR (Toll-like receptor) inhibitors, cytokine inhibitors such as anti-cytokines or anti-cytokine receptors (e.g., IL-1RA for interleukin-1 receptor antagonists), inhibitors of immunostimulants such as G-CSF (granulocyte colony stimulating factor), GM-CSF (granulocyte-macrophage colony stimulating factor), IL-7 (interleukin-7), CD28 antagonist peptides and antibodies, particularly monoclonal antibodies against CD28, and cellular therapies such as adoptive cell therapy.
[0242] In one embodiment, the therapy is selected from the group consisting of checkpoint inhibitors, TLR (Toll-like receptor) inhibitors, cytokine inhibitors such as anti-cytokines or anti-cytokine receptors, G-CSF (granulocyte colony-stimulating factor), IL-7 (interleukin-7), inhibitors of immunostimulants, and cell therapy. In other words, in one embodiment, the therapy comprises or consists of administration of at least one of checkpoint inhibitors, TLR (Toll-like receptor) inhibitors, cytokine inhibitors, G-CSF (granulocyte colony-stimulating factor), IL-7 (interleukin-7), GM-CSF (granulocyte-macrophage colony-stimulating factor), inhibitors of immunostimulants, or cell therapy.
[0243] As used herein, checkpoint inhibitors (CPIs, also known as immune checkpoint inhibitors or ICIs) refer to compounds that block the interaction between inhibitory receptors expressed on T cells and their ligands.Checkpoint inhibitors include antibodies, particularly monoclonal antibodies, and non-antibody inhibitors such as small molecule inhibitors.
[0244] Examples of checkpoint inhibitors include, but are not limited to, inhibitors of the cell surface receptor PD-1 (programmed cell death protein 1), also known as CD279 (cluster of differentiation 279), inhibitors of the ligand PD-L1 (programmed death ligand 1), also known as CD274 (cluster of differentiation 274) or B7-H1 (B7 homolog 1), inhibitors of the cell surface receptor CTLA4 or CTLA-4 (cytotoxic T lymphocyte-associated protein 4), also known as CD152 (cluster of differentiation 152), inhibitors of LAG-3 (lymphocyte activation gene 3), also known as CD223 (cluster of differentiation 223), inhibitors of HAVCR2 (hepatitis A virus inhibitors of TIGIT (T cell immunoreceptor with Ig and ITIM domains), also known as VSIG9 (V-set and immunoglobulin domain containing protein 9) or VSTM3 (V-set and transmembrane domain containing protein 3); inhibitors of BTLA (B and T lymphocyte attenuator), also known as CD272 (cluster of differentiation 272); and inhibitors of CEACAM-1 (carcinoembryonic antigen-related cell adhesion molecule 1), also known as CD66a (cluster of differentiation 66a).
[0245] As used herein, TLR inhibitors (sometimes also referred to as TLR antagonists) refer to compounds that block TLR signaling. TLR inhibitors can act by blocking the binding of TLR ligands to receptors or by blocking intracellular signaling pathways to stop signaling (Gao et al., Front Physiol. 2017;8:508). TLR inhibitors include, but are not limited to, small molecule inhibitors, antibodies, particularly monoclonal antibodies, oligonucleotides, lipid A analogs, microRNAs and nanoinhibitors.
[0246] As used herein, cytokine inhibitor refers to a compound that reduces the synthesis of cytokines, reduces their concentration in free active form, blocks their interaction with specific receptors, or interferes with the signal transduction of cytokine receptors.Cytokine inhibitors include, but are not limited to, antibodies, particularly monoclonal antibodies against cytokines (i.e., anti-cytokine antibodies), antibodies, particularly monoclonal antibodies against cytokine receptors (i.e., anti-cytokine receptor antibodies), cytokine receptor antagonists, and soluble receptors that act as decoy receptors.
[0247] According to one embodiment, the therapy is a therapy that seeks to inhibit or remove endotoxins, also referred to herein as anti-endotoxin therapy.
[0248] Examples of anti-endotoxin therapies include, but are not limited to, endotoxin inhibitors such as anti-endotoxin antibodies, particularly anti-endotoxin monoclonal antibodies, recombinant alkaline phosphatases, e.g., human recombinant AP (recAP), and hemoperfusion, which allows removal of toxins by directly contacting the blood in the extracorporeal circulation with a material that adsorbs toxins, e.g., polymyxin B-immobilized fiber cartridges (PMX-DHP).
[0249] According to one embodiment, the therapy is a vasopressor therapy, in other words, according to one embodiment, the therapy comprises or consists of the administration of a vasopressor.
[0250] Examples of vasopressor therapy include, but are not limited to, administering vasoactive catecholamine hormones such as norepinephrine, dopamine, epinephrine, vasopressin, and / or phenylephrine.
[0251] According to one embodiment, the therapy is an angiogenesis inhibitor, in particular an angiopoietin-2 (Ang-2 or Ang2) inhibitor. In other words, according to one embodiment, the therapy comprises or consists of the administration of an angiogenesis inhibitor, in particular an angiopoietin-2 (Ang-2 or Ang2) inhibitor.
[0252] The angiopoietin-Tie signaling system, particularly angiopoietin-1 (Ang-1) and Tie 2, is a vascular-specific receptor tyrosine kinase pathway essential for normal vascular development. Initially, Ang-2 was identified as an antagonist of Ang-1 and inhibited the activation of Tie2 by Ang-1. However, it remains unclear whether Ang-2 is an antagonist or agonist of Tie2 in the context of vascular remodeling. Several studies have shown that Ang-2 plays a role in inflammation-induced vascular remodeling and tumor angiogenesis and growth (Thurston & Daly, Cold Spring Harb Perspect Med. 2012 Sep 1;2(9):a006550).
[0253] As used herein, Ang-2 inhibitors (sometimes referred to as Ang2 antagonists) refer to compounds that block Ang-2 signal transduction, particularly compounds that block the interaction between Ang-2 and Tie2.According to the present invention, Ang-2 inhibitors therefore include inhibitors that bind to Ang-2 and inhibitors that bind to Tie2. Examples of Ang-2 inhibitors include, but are not limited to, antibodies against Ang-2, in particular monoclonal antibodies, Ang2 blocking antibodies also called ABA (Han et al., Sci Transl Med. 20 Apr 2016;8(335):335ra55), Ang2 binding and Tie2 activating antibodies also called ABTAA (Han et al., Sci Transl Med. 20 Apr 2016;8(335):335ra55), nanobodies against Ang-2, such as bispecific nanobodies that inhibit VEGF (vascular endothelial growth factor) and Ang-2, peptibodies against Ang-2 corresponding to a fusion of an inhibitory Ang-2 binding peptide with an IgFc domain, soluble decoy receptors also called soluble ligand capture receptors, oligonucleotides such as antisense RNA, aptamers such as RNA aptamers that specifically block Ang-2.
[0254] According to one embodiment, the therapy is adrenomedullin (ADM) and adrenomedullin targeted therapy.
[0255] Examples of adrenomedullin and adrenomedullin targeted therapies include, but are not limited to, monoclonal antibodies such as adrenomedullin (ADM), e.g., a bolus of ADM or continuous infusion of ADM, antibodies that recognize ADM (anti-AMD antibodies), e.g., antibodies that recognize biologically active ADM (anti-bio-ADM antibodies), particularly non-neutralizing antibodies such as adrecizumab.
[0256] According to one embodiment, the therapy is a TREM-1 inhibitor, in other words, according to one embodiment, the therapy comprises or consists of the administration of a TREM-1 inhibitor.
[0257] According to the present invention, a TREM-1 inhibitor is an active agent capable of inhibiting the function, activity or expression of TREM-1.
[0258] In one embodiment, the TREM-1 inhibitor is selected from the group consisting of peptides that inhibit the function, activity or expression of TREM-1, antibodies directed to TREM-1 and / or sTREM-1, or TREM-1 and / or sTREM-1 ligands, small molecules that inhibit the function, activity or expression of TREM-1, siRNAs directed to TREM-1, shRNAs directed to TREM-1, antisense oligonucleotides directed to TREM-1, ribozymes directed to TREM-1 and aptamers directed to TREM-1.
[0259] Thus, in one embodiment, the present invention relates to an in vitro method for identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which is susceptible to the administration of a TREM-1 inhibitor as defined above, said method comprising: a) measuring the level of soluble triggering receptor expressed on bone marrow cells-1 (sTREM-1) in a biological sample from a human subject; b) comparing the level of sTREM-1 measured in step a) with the predetermined sTREM-1 value as defined above; and c) identifying a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, having an sTREM-1 level measured in step a) that is higher than the predetermined sTREM-1 value in step b), as being susceptible to administration of said TREM-1 inhibitor.
[0260] Examples of peptides that inhibit the function, activity or expression of TREM-1 include, but are not limited to, peptides that target the TREM-1 ligand, such as, for example, the TLT-1 peptide.
[0261] In one embodiment, the TREM-1 inhibitor is a peptide that inhibits TREM-1 through its binding to a TREM-1 ligand.
[0262] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide.
[0263] In one embodiment, the TREM-1 inhibitor is SEQ ID NO: 7 (MGLTLLLLLLLGLEGQGIVGSLPEVLQAPVGSSILVQCHYRLQDVKAQKVWCRFLPEGCQPLVSSAVDRRAPAGRRTFLTDLGGGLLQVEMVTLQEEDAGEYGCMVDGARGPQILHRVSLNILPPEEEEETHKIGSLAENAFSDPAGSANPLEPSQDEKSIPLIWGAVLLVGLLVAAVVLFAVMAKRKQGNRLGVCGRFLSS RVSGMNPSSVVHHVSDSGPAAELPLDVPHIRLDSPPSFDNTTYTSLPLDSPSGKPSLPAPSSLPPLPPKVLVCSKPVTYATVIFPGGNKGGGTSCGPAQNPPNNQTPSS), or a sequence having at least 60, 65, 70, 75, 80, 85 or 90% identity to the amino acid sequence set forth in SEQ ID NO:7.
[0264] In one embodiment, the TREM-1 inhibitor is a short TLT-1 peptide consisting of 6 to 20 contiguous amino acids derived from human TLT-1 having the amino acid sequence set forth in SEQ ID NO: 7 or a functionally conservative variant or derivative thereof.
[0265] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide consisting of 6 to 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids and comprising an amino acid sequence also referred to as LR17 as set forth in SEQ ID NO:8 (LQEEDAGEYGCMVDGAR), an amino acid sequence also referred to as LR12 as set forth in SEQ ID NO:9 (LQEEDAGEYGCM), an amino acid sequence also referred to as LR6-1 as set forth in SEQ ID NO:10 (LQEEDA), an amino acid sequence also referred to as LR6-2 as set forth in SEQ ID NO:11 (EDAGEY), or an amino acid sequence also referred to as LR6-3 as set forth in SEQ ID NO:12 (GEYGCM), or a sequence having at least 60, 65, 70, 75, 80, 85 or 90% identity to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, respectively.
[0266] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide consisting of 6 to 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids and comprising the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or a function-conservative variant or derivative thereof.
[0267] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide comprising or consisting of an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or a sequence having at least 60, 65, 70, 75, 80, 85 or 90% identity to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, respectively.
[0268] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide comprising or consisting of the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or a function-conservative variant or derivative thereof.
[0269] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide having an amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or a sequence having at least 60, 65, 70, 75, 80, 85 or 90% identity to the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, respectively.
[0270] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide having the amino acid sequence set forth in SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, or SEQ ID NO:12, or a function-conservative variant or derivative thereof.
[0271] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide having the amino acid sequence set forth in SEQ ID NO:9 (also known as LR12 or nangibotide or motrem), or a sequence having at least 60, 65, 70, 75, 80, 85, or 90% identity to the amino acid sequence set forth in SEQ ID NO:9.
[0272] In one embodiment, the TREM-1 inhibitor is a TLT-1 peptide having the amino acid sequence set forth in SEQ ID NO:9, also known as LR12 or nangibotide or motrem, or a function-conservative variant or derivative thereof.
[0273] As used herein, the term "function-conservative variant" refers to a peptide derived from the TLT-1 peptide as described above, in which a given amino acid residue in the peptide has been altered without altering the overall conformation and function of the TLT-1 peptide, including, but not limited to, replacement of an amino acid with one having similar properties (e.g., a similar polarity replaced by another acidic or basic amino acid, an acidic or basic amino acid of similar hydrogen bonding ability, a hydrophobic amino acid replaced by another hydrophobic amino acid, an aromatic amino acid replaced by another aromatic amino acid).
[0274] It is generally known that the percentage of protein or amino acid sequence similarity between any two proteins with similar functions can vary, since amino acids other than those shown to be conserved may differ within a protein, and can be, for example, 70% to 99%, when the similarity is determined according to an alignment method, such as the cluster method based on the MEGALIGN algorithm.
[0275] "Function-conservative variants" also include TLT-1 peptides that have at least 20%, 30%, 40%, 50%, or 60% amino acid identity with the TLT-1 peptides as described above, and have the same or substantially similar properties or functions as the TLT-1 peptides described above, for example as determined by BLAST or FASTA algorithms. Preferably, "function-conservative variants" include TLT-1 peptides that have at least 60%, 65%, 70%, 75%, 80%, 85% or 90% amino acid identity with the TLT-1 peptides as described above, and have the same or substantially similar properties or functions as the TLT-1 peptides described above.
[0276] As used herein, the term "derivative" refers to a variation of a peptide or its function-conservative variants, or otherwise modified to change the conformation, activity, specificity, efficacy or stability of the peptide in vitro or in vivo. For example, the variation may include modification by covalent attachment of any type of molecule to the peptide or by addition of a compound(s) to any amino acid of the peptide.
[0277] In one embodiment, the TLT-1 peptide or function-conservative variant or derivative thereof as described above may have the D or L configuration.
[0278] In one embodiment, the amino acid from the amino terminus of the above TLT-1 peptides or function-conservative variants or derivatives thereof has an acetylated terminal amino group and the amino acid from the carboxyl terminus has an amidated terminal carboxy group.
[0279] Furthermore, the above TLT-1 peptides or their function-conserving variants or derivatives may undergo reversible chemical modification to enhance their bioavailability (such as stability and lipid solubility) and their ability to cross the blood-brain barrier and epithelial tissue. Examples of such reversible chemical modifications include esterification of the carboxyl groups of the amino acids glutamic acid and aspartic acid with alcohols, thereby removing the negative charge of the amino acid and increasing its hydrophobicity. This esterification is reversible, since the formed ester bond is recognized by intracellular esterases that hydrolyze the bond, restoring the charge to the aspartic acid and glutamic acid residues. The net effect is the accumulation of intracellular peptides, since the internalized and de-esterified peptides cannot cross the cell membrane.
[0280] Another example of such a reversible chemical modification is the addition of additional peptide sequences that can increase membrane permeability, such as the TAT peptide or the penetratin peptide (see Charge-Dependent Translocation of the Trojan. A Molecular View on the Interaction of the Trojan Peptide Penetratin with the 15 Polar Interface of Lipid Bilayers. Biophysical Journal, Vol. 87, Issue 1, July 1, 2004, pp. 332-343).
[0281] The above TLT-1 peptides or their function-conservative variants or derivatives can be obtained by conventional methods of solid-phase chemical peptide synthesis according to Fmoc and / or Boc-based methodologies (see Pennington, MW and Dunn, BN (1994) Peptide synthesis protocols. Humana Press, Totowa.).
[0282] Alternatively, the above TLT-1 peptide or function-conserving variant or derivative can be obtained by conventional methods based on recombinant DNA technology, such as, briefly, a method that includes inserting the nucleic acid sequence that codes for the peptide into a suitable plasmid or vector, transforming competent cells for the plasmid or vector, and growing the cells under conditions that allow the expression of the peptide, and, if desired, isolating and (optionally) purifying the peptide or the eukaryotic cell that expresses the peptide through conventional means known to those skilled in these matters.A review of the principles of recombinant DNA technology can be found, for example, in the textbook entitled "Principles of Gene Manipulation: An Introduction to Genetic Engineering" (R.W.Old&S.B.Primrose, Blackwell Scientific Publications, 4th Edition (1989)).
[0283] According to one embodiment, the TREM-1 inhibitor is a TLT-1 peptide as described above, in particular a TLT-1 peptide having the amino acid sequence set forth in SEQ ID NO:9, also known as LR12 or nangibotide or motrem, or a sequence having at least 60, 65, 70, 75, 80, 85 or 90% identity to the amino acid sequence set forth in SEQ ID NO:9, wherein the TLT-1 peptide is to be administered to a human subject by continuous infusion, preferably by continuous intravenous infusion, at a dose ranging from about 0.1 mg / h per kilogram of body weight (mg / kg / h) to about 2.5 mg / kg / h, preferably from about 0.3 mg / kg / h to about 1 mg / kg / h, even more preferably from about 0.3 mg / kg / h to about 0.9 mg / kg / h. In one embodiment, the TLT-1 peptide is administered to a human subject by continuous infusion, preferably by continuous intravenous infusion, at a dose ranging from about 0.15 g / 24 hours to about 4.5 g / 24 hours, preferably from about 0.5 g / 24 hours to about 2 g / 24 hours, and even more preferably from about 0.5 g / 24 hours to about 1.5 g / 24 hours.
[0284] In one embodiment, the TLT-1 peptide is administered to a human subject by continuous infusion, preferably by continuous intravenous infusion, at a dose of about 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1 mg / kg / h, preferably at a dose of about 0.3 mg / kg / h. In one embodiment, the TLT-1 peptide is administered to a human subject by continuous infusion, preferably by continuous intravenous infusion, at a dose of about 0.3 mg / kg / h or about 1 mg / kg / h. In one embodiment, the TLT-1 peptide is administered to a human subject by continuous infusion, preferably by continuous intravenous infusion, at a dose of about 0.15, 0.30, 0.45, 0.60, 0.75, 0.90, 1.05, 1.2, 1.35, 1.5, 1.65, 1.8 or 2 g / 24 hours.
[0285] In one embodiment, TLT-1 peptide is administered to human subject for at least 24 hours and / or up to 5 days.In one embodiment, TLT-1 peptide is administered to human subject for 24 hours, 48 hours, 72 hours, 96 hours or 120 hours.Thus, in one embodiment, TLT-1 peptide is administered to human subject for 1 day, 2 days, 3 days, 4 days or 5 days.
[0286] In one embodiment, a loading dose of TLT-1 peptide is administered prior to the continuous administration of the TLT-1 peptide. In one embodiment, the loading dose of TLT-1 peptide is a dose ranging from about 0.5 mg / kg to about 5 mg / kg. In one embodiment, the loading dose of TLT-1 is a dose of about 0.5, 0.75, 1, 1.25, 1.5, 1.665, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75 or 5 mg / kg, preferably about 1.665 mg / kg or 5 mg / kg. In one embodiment, the loading dose of TLT-1 peptide is administered over about 15 minutes, preferably by intravenous injection. Thus, in one embodiment, the loading dose of TLT-1 peptide is a dose ranging from about 2 mg / kg / h to about 20 mg / kg / h. In one embodiment, the loading dose of the TLT-1 peptide is at a dose of about 2, 3, 4, 5, 6, 6.66, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 mg / kg / h, preferably 6.66 or 20 mg / kg / h.
[0287] According to one embodiment, such therapy is to be administered within the first 2 to 24 hours after initiation of patient care, particularly after initiation of vasopressor therapy.
[0288] In one embodiment, the above therapy is to be administered within the first 2, 3, 6, 9, 12, 15, 18, 21 or 24 hours after initiation of patient care, particularly after initiation of vasopressor therapy.
[0289] In one embodiment, the subject is a human patient who is awaiting or undergoing a medical treatment, or has been / is / will be the subject of a medical treatment, or is being monitored for the onset or progression of a disease such as an inflammatory disorder, preferably SIRS, sepsis or septic shock.
[0290] In one embodiment, the subject is a human patient hospitalized with septic shock.
[0291] In one embodiment, the subject has a documented or suspected infection.
[0292] In one embodiment, the subject has a community-acquired infection. In one embodiment, the subject has a hospital-acquired infection.
[0293] Examples of infections include, but are not limited to, respiratory infections, abdominal infections, and urinary tract infections (UTIs), meningitis, endocarditis, skin infections, bone infections, wound infections, catheter-associated bloodstream infections, and device-associated infections.
[0294] In one embodiment, the subject is male. In another embodiment, the subject is female. In one embodiment, the subject is a pregnant woman.
[0295] In one embodiment, the subject is an adult. In one embodiment, the subject is an elderly person. In one embodiment, the subject is a child. In one embodiment, the subject is an infant. In one embodiment, the subject is a neonate.
[0296] In one embodiment, the subject is not immunocompromised, immunosuppressed or immunodeficient. In another embodiment, the subject is immunocompromised, immunosuppressed or immunodeficient. In another embodiment, the subject is undergoing immunosuppressive therapy.
[0297] In one embodiment, the subject suffers from a chronic medical condition such as atrial fibrillation, cancer, chronic kidney disease, chronic lung disease, cirrhosis, coronary artery disease, deep vein thrombosis, diabetes, dyslipidemia, endocarditis, hypertension, influenza, malaria, or any other protozoan parasitic disease, myocardial infarction, neurological disease, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), peripheral arterial disease, pulmonary fibrosis, severe obesity, and stroke.
[0298] According to one embodiment, the inflammatory disorder comprises or is selected from the group consisting of systemic inflammatory response syndrome (SIRS), sepsis, septic shock, sepsis-associated organ dysfunction, acute respiratory distress syndrome (ARDS), severe acute respiratory syndrome (SARS), acute kidney injury (AKI), pancreatitis, inflammatory bowel disease, pneumonia, endotoxemia and hemorrhagic shock.
[0299] According to one embodiment, the inflammatory disorder is an acute inflammatory disorder.
[0300] Examples of acute inflammatory disorders include, but are not limited to, systemic inflammatory response syndrome (SIRS), sepsis, septic shock, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), pancreatitis, and hemorrhagic shock.
[0301] In one embodiment, the acute inflammatory disorder comprises or is selected from the group consisting of systemic inflammatory response syndrome (SIRS), sepsis, septic shock, acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), pancreatitis and hemorrhagic shock.
[0302] According to one embodiment, the inflammatory disorder includes or is selected from the group consisting of systemic inflammatory response syndrome (SIRS), sepsis, septic shock, acute respiratory distress syndrome (ARDS) and acute kidney injury (AKI).
[0303] In one embodiment, the inflammatory disorder is systemic inflammatory response syndrome (SIRS), sepsis or septic shock.
[0304] In one embodiment, the inflammatory disorder is septic shock.
[0305] Systemic inflammatory response syndrome (SIRS) is characterized by systemic inflammation and widespread tissue damage. Clinically, SIRS is defined as meeting at least two of the following four criteria: fever >38.0°C or hypothermia <36.0°C, tachycardia >90 beats / min, tachypnea >20 breaths / min, and leukocytosis >12x10 9 / L or leukopenia <4x10 9 / L (Bone et al., Chest. 1992 June;101(6):1644-55). SIRS can occur as a response to non-specific insults of either infectious or non-infectious origin. Examples of insults of non-infectious origin include, but are not limited to, trauma, burns, pancreatitis, autoimmune diseases, and surgery. Examples of insults of infectious origin include bacterial infections (e.g., respiratory infections, abdominal infections, and urinary tract infections (UTIs), fungal infections (e.g., respiratory infections) and viral infections (e.g., respiratory infections).
[0306] As mentioned above, sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated response of a human subject to an infection (Singer et al., JAMA. 2016 Feb. 23; 315(8):801-10). A patient with sepsis may be clinically identified as a patient suffering from documented or suspected infection and organ dysfunction. In one embodiment, organ dysfunction in a human subject may be identified using an organ dysfunction score, i.e., a score used to assess organ dysfunction in a human subject, particularly upon admission to an ICU or emergency room. Examples of organ dysfunction scores include, but are not limited to, the SOFA score, qSOFA score, MODS (Multiple Organ Dysfunction Score), P-MODS (Pediatric Multiple Organ Dysfunction Score), and LODS (Logistic Organ Dysfunction System). In one embodiment, organ dysfunction in a human subject may be identified as an acute change in total SOFA score of 2 or more points as a result of an infection (Singer et al., JAMA. 2016 Feb. 23; 315(8):801-10). The baseline SOFA score can be considered to be zero in patients who are not known to have pre-existing organ dysfunction (Singer et al., JAMA. 2016 Feb. 23;315(8):801-10).
[0307] Septic shock is defined as a subset of sepsis, in which particularly severe cardiovascular, cellular, and metabolic abnormalities are associated with a higher risk of death than sepsis alone. Thus, sepsis encompasses septic shock. Patients with septic shock can be identified clinically as those with sepsis who (i) have persistent hypotension requiring vasopressors to maintain mean arterial pressure above 65 mmHg despite adequate volume resuscitation, and (ii) have serum lactate levels above 2 mmol / L (18 mg / dL) (Sepsis-3 definition as described in Singer et al., JAMA. 2016 Feb 23;315(8):801-10). With these criteria, hospital mortality is greater than 40% (Singer et al., JAMA. 2016 Feb 23;315(8):801-10).
[0308] In one embodiment, the infection that induces a dysregulated response in a human subject suffering from SIRS, sepsis or septic shock is a bacterial infection, a fungal infection, or a viral infection.
[0309] Examples of infections include, but are not limited to, respiratory infections, abdominal infections, and urinary tract infections (UTIs).
[0310] According to one embodiment, human subjects suffering from SIRS, sepsis or septic shock can be evaluated using severity scores, i.e., scores used to evaluate the severity and / or prognosis of disease at the time of admission to ICU or emergency room.Examples of severity scores include, but are not limited to, APACHE II score, APACHE III score, APACHE IV score, SAPS score, SAPS II score, and SAPS3 score.
[0311] In one embodiment, human subjects suffering from SIRS, sepsis or septic shock may be evaluated using the APACHEII (see Acute Physiology and Chronic Health Evaluation II) scoring system. APACHEII is commonly used to assess the severity of disease and determine the prognosis of adult patients admitted to intensive care units. APACHEII provides a general measure of disease severity using a point score ranging from 0 to 71 based on an initial set of 12 routine physiological measurements, age, and previous health conditions (Knaus et al., Crit Care Med. 1985 Oct;13(10):818-29). APACHEII scores may be determined in the first 24 hours upon admission to the intensive care unit (ICU) or emergency room. Higher scores are associated with higher predicted mortality, with a score of 25 representing a 50% predicted mortality and a score above 35 representing an 80% predicted mortality.
[0312] In one embodiment, the human subject suffering from SIRS, sepsis or septic shock has an APACHE II score of less than 34. In one embodiment, the human subject suffering from SIRS, sepsis or septic shock is not moribund.
[0313] In one embodiment, human subjects suffering from SIRS, sepsis or septic shock can be assessed using the APACHEIII (see Acute Physiology and Chronic Health Evaluation III) scoring system. APACHEIII is redefined from the APACHEII scoring system to more accurately predict the risk of hospital mortality in critically ill hospitalized adults (Knaus et al., Chest. 1991 December;100(6):1619-36).
[0314] In one embodiment, human subjects suffering from SIRS, sepsis or septic shock may be assessed using the APACHEIV (see Acute Physiology and Chronic Health Evaluation IV) scoring system. APACHEIV is an improved and updated model for estimating risk of short-term mortality as well as predicting length of stay in the intensive care unit (ICU) (Zimmerman et al., Crit Care Med. 2006 May;34(5):1297-310). The APACHEIV scoring system takes into account more variables, particularly the effect of mechanical ventilation, thrombolysis, sedation on the Glasgow Coma Scale, rescaled Glasgow Coma Scale, PaO2 / FiO2 ratio, and disease-specific subgroups. APACHEIV uses a point score ranging from 0 to 286.
[0315] In one embodiment, human subjects suffering from SIRS, sepsis or septic shock may be assessed using the SAPSII (see "Simplified Acute Physiological Score II") scoring system. SAPSII is a scoring system for estimating in-hospital mortality in adult patients admitted to an intensive care unit (ICU). SAPSII includes 17 variables, 12 physiological variables, age, type of admission, and three variables related to underlying disease (Le Gall et al., JAMA. 1993 Dec. 22-29;270(24):2957-63). SAPSII uses a point score ranging from 0 to 163.
[0316] In one embodiment, human subjects suffering from SIRS, sepsis or septic shock may be assessed using the SAPS3 (see "Simplified Acute Physiological Score III") scoring system. SAPS3 is a scoring system for predicting hospital mortality in patients admitted to the intensive care unit (ICU) (Metnitz et al., Intensive Care Med. 2005 October;31(10):1336-1344 and Moreno et al., Intensive Care Med. 2005 October;31(10):1345-55). SAPS3 is based on 20 different variables.
[0317] As described above, the presence of organ dysfunction associated with sepsis or septic shock may be assessed using organ dysfunction scores such as the SOFA score, qSOFA score, MODS (Multiple Organ Dysfunction Score), P-MODS (Pediatric Multiple Organ Dysfunction Score), or LODS (Logistic Organ Dysfunction System).
[0318] The Sequential Organ Failure Assessment (SOFA) score (originally termed Sepsis-Associated Organ Failure Assessment, Vincent et al., Intensive Care Med. 1996 July;22(7):707-10) is a commonly used scoring system to assess organ dysfunction in human subjects, especially upon admission to an ICU or emergency room. The SOFA scoring system (Vincent et al., Crit Care Med. 1998 November;26(11):1793-800) relies on assessment of the respiratory system (i.e., PaO2 / FiO2 (mmHg)), nervous system (i.e., Glasgow Coma Scale), cardiovascular system (i.e., mean arterial pressure or administration of vasopressors required), liver function (i.e., bilirubin (mg / dL or μmol / L)), coagulation (i.e., platelet count), renal function (i.e., creatinine (mg / dL or μmol / L) or urine volume (mL / d)).
[0319] The baseline SOFA score can be considered to be zero in patients not known to have pre-existing (acute or chronic) organ dysfunction prior to the onset of infection. A SOFA score of at least 2 points reflects an overall mortality risk of approximately 10% in a general hospital population with suspected infection (Singer et al., JAMA. 2016 Feb 23;315(8):801-10).
[0320] In one embodiment, the human subject is suffering from SIRS, sepsis or septic shock associated with a SOFA score of at least 2 points.
[0321] In one embodiment, the human subject is suffering from SIRS, sepsis or septic shock associated with organ dysfunction defined as an acute change in SOFA score of at least 2 points.
[0322] The presence of organ dysfunction associated with sepsis or septic shock can also be assessed using the Quick SOFA score (also called quickSOFA or qSOFA). The qSOFA scoring system relies on three criteria: respiratory rate ≥ 22 breaths / min, impaired consciousness (Glasgow Coma Scale < 15), and systolic blood pressure ≥ 100 mmHg (Seymour et al., JAMA. 2016 Feb 23;315(8):762-74).
[0323] In one embodiment, the human subject is suffering from SIRS, sepsis or septic shock associated with a qSOFA score of at least 2 points.
[0324] In one embodiment, the human subject is suffering from SIRS, sepsis or septic shock associated with organ dysfunction defined as an acute change in qSOFA score of at least 2 points.
[0325] According to one embodiment, the human subject is suffering from septic shock.
[0326] According to one embodiment, the human subject suffers from SIRS, sepsis or septic shock, preferably septic shock, and is receiving standard treatment.Standard treatment, particularly septic shock standard treatment, can include but is not limited to fluid therapy, vasopressor therapy as described above, cardiovascular support, respiratory support (such as artificial respiration), renal support and / or sedation.Thus, in one embodiment, the human subject suffers from SIRS, sepsis or septic shock, preferably septic shock, and is receiving fluid therapy, vasopressor therapy as described above, cardiovascular support, respiratory support (such as artificial respiration), renal support and / or sedation.
[0327] According to the invention, a human subject suffering from an inflammatory disorder identified by the above methods, preferably SIRS, sepsis or septic shock, is likely to respond to a therapy, in particular the administration of a TREM-1 inhibitor, as described above.
[0328] According to one embodiment, the aim of the above method is to identify a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, which human subject is a "responder", i.e. responds or is likely to respond to a treatment as described above, in particular the administration of a TREM-1 inhibitor.
[0329] Conversely, in the present invention, a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, who is a "non-responder" is a human subject who does not respond or is poorly responsive to a therapeutic method, in particular to the administration of a TREM-1 inhibitor as described above.
[0330] According to one embodiment, for a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, the response to a therapy as described above, in particular to the administration of a TREM-1 inhibitor, is characterized by at least one of the following occurring after administration of the TREM-1 inhibitor: - reversal of hypotensive shock, preferably during or after the administration period of therapy (preferably a TREM-1 inhibitor), e.g., for 6 hours, 12 hours, 18 hours or 24 hours after the end of administration, where reversal of shock is defined as the absence of any vasopressor therapy during the 24 hour period (i.e., no need to restart vasopressor therapy within 24 hours after the end of vasopressor therapy), - A reduction in severity scores (such as APACHEII score, APACHEIII score, APACHEIV score, SAPS score, SAPSII score, or SAPS3 score) used to assess the severity and / or prognosis of a disease in a human subject suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, upon admission to the ICU or emergency room; - A reduction in organ dysfunction scores (such as SOFA score, qSOFA score, MODS (Multiple Organ Dysfunction Score), P-MODS (Pediatric Multiple Organ Dysfunction Score), or LODS (Logistic Organ Dysfunction System)) used to assess the presence of organ dysfunction in human subjects suffering from an inflammatory disorder, preferably SIRS, sepsis or septic shock, upon admission to an ICU or emergency room, - a decrease in the SOFA score and / or qSOFA score, preferably with reference to the SOFA score and / or qSOFA score assessed at the time of admission to the ICU or emergency room or before the start of administration of the therapy, in particular over 1, 2, 3, 4, 5, 6 or 7 days after the start of administration of the therapy (preferably a TREM-1 inhibitor), in one embodiment the decrease in the SOFA score is a decrease of at least 1 point (also referred to as delta-1 point or ΔSOFA-1 point), preferably at least 1.5 points, in particular on the 3rd or 5th day after the start of administration of the therapy, preferably with reference to the SOFA score and / or qSOFA score assessed at the time of admission to the ICU or emergency room or before the start of administration of the therapy, - a reduction in the need for cardiovascular support, e.g. preferably with reference to the need for cardiovascular support upon admission to the ICU or emergency room or prior to the start of the treatment, in particular the use of vasopressor therapy over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment (preferably a TREM-1 inhibitor); - a reduction in the need for respiratory support, e.g. preferably with reference to the need for respiratory support upon admission to the ICU or emergency room or before the start of the treatment, in particular the use of invasive mechanical ventilation (IMV) over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment, preferably a TREM-1 inhibitor, - a reduced need for renal support, e.g. preferably with reference to the need for renal support at the time of admission to the ICU or emergency room or before the start of the treatment, in particular the use of continuous or non-continuous renal replacement therapy, also called RRT (such as dialysis), over 1, 2, 3, 4, 5, 6 or 7 days after the start of the treatment (preferably a TREM-1 inhibitor); - a reduced risk of reinfection, in particular 28 days, 90 days or 365 days after a first inflammatory disorder, in particular a first infection causing an inflammatory disorder, - absence of reinfection, especially 28 days, 90 days or 365 days after the initial inflammatory disorder, especially after the initial infection causing the inflammatory disorder, - a reduced risk of re-hospitalisation, particularly re-infection 28, 90 or 365 days after the initial inflammatory disorder, particularly the initial infection causing the inflammatory disorder; - No readmission, specifically no readmission within 28, 90 or 365 days after the initial admission; - an increased chance of survival, in particular surviving 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 years after initiation of administration of a therapy (preferably a TREM-1 inhibitor), in one embodiment the chance of survival, in particular in subjects with multiple comorbidities, is preferably assessed with the Charlson Comorbidity Index (CCI), with reference to the CCI assessed at the time of admission to the ICU or emergency room or before initiation of administration of the therapy, and an increased chance of survival at 10 years corresponds to a decrease in the Charlson Comorbidity Index, - a reduced risk of sepsis-related death, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - A reduction in the risk of all-cause death, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - a reduced risk of post-septic or post-shock morbidity, particularly at days 5, 28, 90 or 365 after initiation of therapy (preferably a TREM-1 inhibitor); - improved quality of life, especially post-sepsis or post-shock quality of life, which can be assessed, for example, by assessment of survival and quality-adjusted life years (QALYs) estimated from EQ5D. For example, a health-related quality of life (HRQoL) score of EQ 5D 5L can be calculated and converted into a utility score, especially at 3, 6, 9, 12, 18, 24 or 36 months after the start of the treatment. - a reduction in the levels of inflammatory markers such as, for example, CRP or IL6, IL-8, IL-10, MCP-1 and TNF-α, in particular over 1, 2, 3, 4, 5, 6 or 7 days after initiation of treatment with a therapy (preferably a TREM-1 inhibitor), preferably with reference to levels assessed upon admission to the ICU or emergency room or before initiation of treatment with a therapy, or - A reduction in levels of markers of endothelial damage, such as, for example, Ang-2, VCAM-1, VGEFR-1 and E-selectin, preferably with reference to levels assessed upon admission to the ICU or emergency room or prior to initiation of therapy, in particular over 1, 2, 3, 4, 5, 6 or 7 days after initiation of therapy (preferably a TREM-1 inhibitor).
[0331] In one embodiment, a human subject as described above suffering from SIRS, sepsis or septic shock, preferably septic shock, and susceptible to a therapy, in particular administration of a TREM-1 inhibitor, i.e. a responder, is a human subject suffering from SIRS, sepsis or septic shock, preferably septic shock, and preferably susceptible to reversing hypotensive shock within the administration period of a therapy (in particular a TREM-1 inhibitor) or after an administration period of, for example, 6 hours, 12 hours, 18 hours or 24 hours after the end of administration, where hypotensive shock reversal is defined as the absence of any vasopressor therapy during the 24 hours (i.e. no need to resume vasopressor therapy 24 hours after the end of vasopressor therapy).
[0332] Conversely, in one embodiment, a human subject suffering from SIRS, sepsis or septic shock, preferably septic shock, that is unlikely to respond to a therapy, in particular the administration of a TREM-1 inhibitor as described above, i.e. a non-responder, is a human subject suffering from SIRS, sepsis or septic shock, preferably septic shock, in which reversal of hypotensive shock cannot occur within the administration period of a therapy (in particular a TREM-1 inhibitor) or, for example, after a period of 6, 12, 18 or 24 hours after the end of administration, where hypotensive shock reversal is defined as the absence of any vasopressor therapy during a 24 hour period, or a human subject suffering from SIRS, sepsis or septic shock, preferably septic shock, that needs to resume vasopressor therapy within 6, 12, 18 or 24 hours after discontinuation of a therapy (in particular a TREM-1 inhibitor).
[0333] In one embodiment, the responder is a human subject suffering from SIRS, sepsis or septic shock, who is susceptible to a reduced Sequential Organ Failure Assessment (SOFA) score following administration of a TREM-1 inhibitor, as described above.
[0334] In one embodiment, the responder is a human subject suffering from SIRS, sepsis or septic shock and is likely to have a reduced Sequential Organ Failure Assessment (SOFA) score following administration of a TREM-1 inhibitor as described above, with reference to a SOFA score assessed upon admission to the ICU or emergency room or prior to initiation of administration of therapy.
[0335] As used herein, the difference in SOFA score following administration of a TREM-1 inhibitor may also be referred to as the delta SOFA score or ΔSOFA score, particularly with reference to the SOFA score assessed upon admission to the ICU or emergency room, or prior to the initiation of administration of therapy.
[0336] In one embodiment, the responder is a human subject suffering from SIRS, sepsis or septic shock, who is likely to have a reduction in SOFA score of at least 1 point, preferably at least 1.5 points, following administration of a TREM-1 inhibitor as described above, particularly with reference to the SOFA score assessed upon admission to the ICU or emergency room or before the start of administration of a therapy.
[0337] Thus, in one embodiment, the responder is a human subject suffering from SIRS, sepsis or septic shock and is likely to have a delta SOFA score (ΔSOFA score) of at least -1 point (minus one point), preferably at least -1.5 points (minus one and a half points) after administration of a TREM-1 inhibitor as described above.
[0338] In one embodiment, the reduction in SOFA score, particularly a reduction of at least 1 point, preferably at least 1.5 points, is assessed on the 1st, 2nd, 3rd, 4th, 5th, 6th or 7th day after initiation of administration of the therapy, preferably the 3rd or 5th day after initiation of administration of the therapy.
[0339] Thus, in one embodiment, the delta SOFA score (ΔSOFA score) is the delta SOFA score assessed on the 1st, 2nd, 3rd, 4th, 5th, 6th or 7th day after initiation of administration of the therapy, preferably on the 3rd or 5th day after initiation of administration of the therapy.
[0340] Herein, applicants show that by measuring levels of soluble TREM-1 (sTREM-1) in biological samples from human subjects suffering from septic shock and comparing those measured sTREM-1 levels to a predefined sTREM-1 value, it is possible to identify human subjects suffering from septic shock who are likely to respond to a TREM-1 inhibitor. In particular, applicants show that human subjects suffering from septic shock who have circulating levels of sTREM-1 higher than a predefined median sTREM-1 level in a reference population of human subjects suffering from septic shock are more likely to respond to, and thus benefit from, administration of a TLT-1 peptide that inhibits TREM-1 activity.
[0341] Prompt patient care is essential for the prognosis of subjects suffering from SIRS, sepsis or septic shock.
[0342] Measurement of the level of sTREM-1, particularly the level of sTREM-1 protein, can be carried out very quickly, particularly in point-of-care testing (POCT) or bedside testing, or in central laboratory assays (tests performed near patients).Thus, the level of sTREM-1 can be measured immediately after the onset of SIRS, sepsis, or septic shock, after the diagnosis of SIRS, sepsis, or septic shock in a human subject, after the hospitalization of a human subject for SIRS, sepsis, or septic shock, particularly in an ICU or emergency room, or after the start of vasopressor therapy.Thus, results can be available within the first 2, 3, 6, 9, 12, 15, 18, 21, or 24 hours, and treatment plan can be determined immediately thereafter. [Brief description of the drawings]
[0343] [Figure 1]Figure 1A shows that release of sTREM-1 is dependent on TREM-1 dimerization. (Fig. 1A) TREM-1 expression by flow cytometry in U937 (gray) and U937-vitD cells (dark grey) compared to isotype control (light grey). (Fig. 1B) A series of photographs showing TREM-1 expression and staining of cell nuclei by confocal microscopy. White arrows indicate clustering and dimerization of TREM-1 at the membrane of U937-vitD cells after incubation with LPS. (Fig. 1C) Graph showing sTREM-1 concentration in the supernatant of U937 and U937-vitD cells, either resting or after incubation with APMA, Pro-MMP9, Act-MMP9, or LPS (100 ng / mL as indicated) for 30 min. LOQ: limit of quantification. [Diagram 2] A series of graphs showing that baseline TREM-1 correlates with 28-day mortality. ROC plot (FIG. 2A) and Kaplan-Meier plot (FIG. 2B) by quartiles of 28-day mortality. Mortality (day 28) per quartile is 12%, 30%, 37%, and 49% for Q1 to Q4, respectively. Overall mortality is 32%. The optimal cut point was determined to be at 408 pg / mL. [Diagram 3] A series of box plots of sTREM-1 at baseline (day 1) for (A) 28-day mortality and (B) 90-day mortality. Kruskal-Wallis test chi-square is 28.8 and 29.5, respectively (both p<0.0001). [Figure 4] A series of box plots of sTREM-1 at day 2 for (A) 28-day mortality and (B) 90-day mortality. Kruskal-Wallis test chi-square is 30.2 and 30.8, respectively (both p<0.0001). [Diagram 5] A series of box plots of sTREM-1 at day 3 for (A) 28-day mortality and (B) 90-day mortality. Kruskal-Wallis test chi-square is 16.9 (p=0.0001) and 19.1 (p=0.0002). [Figure 6] Series of box plots of sTREM-1 on renal replacement therapy (RRT) at admission (RRT adm) and during ICU stay (post-RRT) on (A) day 1 (B) day 2 (C) day 3. Kruskal-Wallis test chi-square is 54.7 (p<0.0001), 68.7 (p<0.0001) and 44 (p<0.0001), respectively. [Figure 7] 1 is a scheme showing the two stages of a Phase IIa clinical trial evaluating administration of nangibotide (also known as motrem) to patients with septic shock (NCT03158948). [Figure 8] 1 is a scheme showing the randomization of patients in each treatment group. [Figure 9] 1 is a series of graphs showing the pharmacokinetics of nangibotide. (A) Nangibotide kinetics in each group (i.e., patients receiving 0.3 mg / kg / h, patients receiving 1.0 mg / kg / h, and patients receiving 3.0 mg / kg / h) from the start of infusion (day 0) to the end of infusion (day 5) and (B) Nangibotide kinetics in each group (i.e., patients receiving 0.3 mg / kg / h, patients receiving 1.0 mg / kg / h, and patients receiving 3.0 mg / kg / h) after the end of infusion. Circles: 0.3 mg / kg / h; Squares: 1 mg / kg / h; Triangles: 3 mg / kg / h. [Figure 10] A series of graphs showing change in SOFA assessment over time relative to baseline (LOCF) in (A) the overall population, (B) patients with low sTREM-1 at baseline (median <433 pg / mL), and (C) patients with high sTREM-1 at baseline (median ≥433 pg / mL). [Figure 11] 1 is a series of graphs showing organ support-free days in patients with high levels of sTREM-1 (median >433 pg / mL) at baseline: (A) days surviving free of vasopressors, (B) days surviving free of invasive mechanical ventilation (IMV), and (C) days surviving free of renal failure and continuous renal replacement therapy (CRRT). [Figure 12]1 is a series of graphs showing the change in Ang-2 concentration from baseline on days 3 (A) and 5 (B) in "All" (corresponding to the entire population), the "G1" subgroup (corresponding to patients with low sTREM-1 at baseline, i.e., <433 pg / mL median), and the "G2" subgroup (corresponding to patients with high sTREM-1 at baseline, i.e., >433 pg / mL median). [Figure 13] 1 is a series of graphs showing the change in IL-6 concentration from baseline on days 3 (A) and 5 (B) in "All" (corresponding to the entire population), the "G1" subgroup (corresponding to patients with low sTREM-1 at baseline, i.e., <433 pg / mL median), and the "G2" subgroup (corresponding to patients with high sTREM-1 at baseline, i.e., >433 pg / mL median). [Figure 14] (A) A series of graphs showing the association between sTREM-1 change at day 5 / EOI (end of infusion) from baseline in the all population in subgroup G1 (patients with sTREM-1 baseline below the median) and subgroup G2 (patients with sTREM-1 baseline above the median) and (B) delta SOFA at day 5 (delta between day 5 / EOI and baseline).
[0344] Working Example The present invention is further illustrated by the following examples. Example 1: material and method Cell culture and stimulation
[0345] The human myelomonocytic cell line U937 (Culture Collections, Public Health England No. 85011440) was cultured in RPMI 1640 Glutamax supplemented with 10% fetal bovine serum, 25 mM Hepes, 100 U / ml penicillin and streptomycin (all from Thermo Fisher Scientific, USA). For some experiments, U937 cells were cultured under the same conditions supplemented with 100 nM 1,25-dihydroxyvitamin D3 (Sigma-Aldrich, USA) to induce upregulation of TREM-1 (U937-vitD cells). For release experiments, Pro-MMP-9 was activated by preincubation with 1 mM APMA for 24 h at 37°C. Cells were cultured at 0.5x10 6 Cells were seeded at 1000 cells / mL and stimulated with E. coli 0127:B8 LPS (10 μg / mL; Sigma-Aldrich), Pro-MMP-9 (1 μg / mL; R&D systems, Abingdon, UK), ρ-aminophenylmercuric acetate (APMA; 1 mM; Sigma-Aldrich), and APMA-activated MMP-9 (1 μg / mL) for 30 min at 37°C. Cell supernatants were collected and sTREM-1 was measured using the Human TREM-1 Quantikine ELISA Kit (Biotechne, R&D Systems) according to the manufacturer's instructions. FACS analysis
[0346] TREM-1 expression was detected by FACS after staining with 5 μL allophycocyanin (APC)-conjugated mouse monoclonal anti-human TREM-1 or corresponding isotype APC antibodies (Miltenyi Biotec, German) for 30 min at 4 °C in the dark. After two washes with PBS, cells were resuspended and fixed with 4% paraformaldehyde. Analysis was performed using an Accuri C6 flow cytometer (Becton Dickinson, San Jose, CA, USA). Confocal microscopy
[0347] 0.3x10 cells 6Cells / well were seeded and stimulated with LPS of E. coli 0127:B8 (1 μg / mL; Sigma-Aldrich) for 1 h in a LabTek chamber (Thermo Fisher Scientific). After stimulation, cells were washed, fixed with paraformaldehyde (4%) for 20 min, permeabilized with Triton 0.1% for 30 min, and then incubated with primary antibody (anti-hTREM-1-AF488; Bioss, USA) overnight at 4 °C. Nuclei were stained with TO-PRO-3 (1 μg / mL; Invitrogen, USA) for 1 h at 37 °C. After washing, coverslips were mounted using a solution of Vectashield (Vector Laboratories, USA). Confocal images were obtained using a Leica SP5 confocal laser scanning microscope system (Leica, Germany) equipped with appropriate filter sets and obtained in sequential scanning mode. result sTREM-1 is a marker for activation of TREM-1.
[0348] We have already described that dimerization of TREM-1 is essential for its activation in innate immune cells (Carrasco et al., Cell Mol Immunol. March 22, 2018). This is triggered by the initial engagement of TLRs. Indeed, stimulation of human primary monocytes and neutrophils was able to induce the recruitment and clustering of TREM-1 at the membrane. Thus, it was confirmed that the dimeric configuration of TREM-1 is the active conformation of the receptor, capable of binding its endogenous ligand and inducing the activation of downstream intracellular pathways. It has previously been demonstrated that metalloproteinases are involved in the release of the TREM-1 ectodomain through the proteolytic cleavage of its long juxtamembrane linker (Gomez-Pina et al., J Immunol. September 15, 2007;179(6):4065-73). We show here that this release requires dimerization of TREM-1, suggesting that release of sTREM-1 is possible only if the receptor is in its active conformation. TREM-1 is expressed at very low levels in resting U937 cells and is upregulated when vitamin D is added to the culture medium (Figure 1A). To investigate whether the proteolytic cleavage of TREM-1 and the subsequent release of sTREM-1 are related to the active conformation of TREM-1, sTREM-1 was measured in the supernatants of U937 and U937-vitD cells after incubation with LPS and / or Act-MMP9 for 15 min. TREM-1 expression was diffuse at the membrane of resting U937-vitD cells, and LPS was able to induce clustering and dimerization of TREM-1 at the membrane (Figure 1B, white arrows). sTREM-1 was not detectable in the supernatant of U937 cells after stimulation with LPS or addition of activated MMP9 (Ac-MMP9). Incubation of U937-vitD cells with LPS or Act-MMP9 alone was not associated with the release of sTREM-1. Interestingly, sTREM-1 was released by U937-vitD cells only when U937-vitD was co-stimulated with LPS and Act-MMP9 (Fig. 1C).These results confirm that MMP9-induced proteolytic cleavage of TREM-1 is possible only when TREM-1 is in the dimeric state, which is the active conformation of the receptor, and therefore sTREM-1 may be a reliable biomarker of TREM-1 receptor activation. Example 2: material and method sTREM-1 Measurement: A Validated ELISA Method for the Quantitative Measurement of sTREM-1 in Human K2-EDTA Plasma
[0349] For routine assays, quantitative measurements of sTREM-1 were performed using a commercially available kit (Human TREM-1 Quantikine ELISA, BioTechne, R&D Systems) and quality control (QC) samples at three concentration levels: QC Low (101 pg / mL), QC Mid (532 pg / mL), and QC High (1080 pg / mL).
[0350] A pre-study assay qualification run was performed to determine the in-run precision and accuracy of the assay. The pre-study assay qualification run consisted of calibration standards and QC samples at five concentration levels (LLOQ (41.3 pg / mL), low, medium, high, and ULOQ (1440 pg / mL) and each QC sample should be processed in six plates in each assay. For each concentration level, fewer than five of the six values should not be used in the final calculation of in-run precision and imprecision. In-run precision should be ≤20% (25% at LLOQ and ULOQ) and in-run imprecision should be within ±20% (25% at LLOQ and ULOQ). Pre-study assays should be validated in triplicate before commencing routine assay.
[0351] Standard (STD) samples were prepared freshly for each analytical day using calibrator diluent RD5-18 and the human TREM-1 standard from the kit. STD samples were adjusted to obtain 10 points of the calibration curve (3000, 2000, 1000, 750, 500, 250, 125, 62.5, 31.3, and 15.6 pg / mL). Calibration standards at 3000 pg / mL and 15.6 pg / mL were used as anchor points (Lowest Calibration Standard (LCS) and Highest Calibration Standard (HCS) of the calibration curve).
[0352] 100 μL of Assay Diluent RD1-27 was added to each well. Then, 50 μL of standard, QC, or sample was added per well. The plate is incubated at 450 rpm on a microplate shaker at room temperature for 2 hours. After 2 hours of incubation, the plate is manually washed three times with wash buffer and 200 μL of human TREM-1 conjugate was added to each well. The plate is supplementally incubated at 450 rpm on a microplate shaker at room temperature for 2 hours. After washing, 200 μL of substrate solution was added to each well. The plate was incubated at room temperature in the dark for 30 minutes. The optical density (OD) was read at 650 nm (pre-read) and when the OD (650 nm) of the HCS was approximately 1.0, 50 μL of stop solution was added to each well. Then, the OD (450 nm) of each well within 30 minutes was measured.
[0353] Calibration curves were obtained by plotting the optical density and concentration of the calibration standards using a logistic curve (4-PL) and a 1 / y2 weighting factor.
[0354] Calibration standards between 2000 and 31.3 pg / mL were excluded from the final calibration curve only if the back-calculated imprecision was outside the range of ±20% (±25% for LCS and HCS), or for reasons of instrument failure, or if there were documented problems during preparation or assay, or if the coefficient of variation (CV%) of concentrations during replicate measurements (n=2 wells per calibration standard) exceeded 20%. No more than 30% of these calibration standards could be excluded from the calibration standards for each series, and the final calibration curve must include at least six non-zero calibration concentration levels, such as LCS and HCS. A blank (0.00 pg / mL) composed of Calibrator Diluent RD5-18 was not used in the calculation of the calibration curve.
[0355] Each routine run included six QC samples (n=2 replicates at three concentration levels). At least four of the six QC samples must be within the acceptance criteria (at least one value within the acceptance criteria at each concentration level). The acceptance criteria were defined as follows: The calculated individual imprecision (n=2 wells per sample) of the replicate concentrations should be within ±20% compared to the nominal value. The coefficient of variation (CV%) of the replicate concentrations should be ≤20%.
[0356] The coefficient of variation (CV%) of replicate concentrations of test samples (n=2 wells per test sample) should also be less than or equal to 20%. Evaluation of sTREM-1 in the AdrenOSS cohort (NCT02393781)
[0357] This study was an ancillary investigation of septic shock patients from the AdrenOSS study (NCT02393781), a European prospective observational multinational study conducted in 24 centers in five countries (France, Belgium, the Netherlands, Italy, and Germany). Patients were recruited from June 2015 to May 2016. The study protocol was approved by the local ethics committee and was performed in accordance with Directive 2001 / 20 / EC, Good Clinical Practices (ICH version 4 of 1 May 1996 and decision of 24 November 2006) and the Declaration of Helsinki. Enrolled patients were aged 18 years or older and were either (i) admitted to the ICU for sepsis or septic shock or (ii) transferred from another ICU in sepsis and septic shock conditions less than 24 hours after primary admission. If patients were treated with vasopressors, they were considered eligible only if treatment was initiated within a maximum of 24 hours of primary admission before ICU admission. Once eligible, patients were stratified by severe sepsis and septic shock based on the definitions of sepsis and organ failure since 2001. Exclusion criteria were pregnancy, vegetative state coma, and participation in an intervention trial in the previous month. Informed consent was obtained from all patients or their legal representatives before enrollment in the study. Patients were treated according to current guidelines, and all treatments and procedures were registered. sTREM-1 was measured in blood samples taken at baseline (also called day 1 or d1), day 2 (d2), and day 3 (d3). Statistical analysis of the AdrenOSS cohort
[0358] Analyses were performed for 293 patients with septic shock. Demographic and baseline characteristics were summarized in a descriptive manner within each population, and categorical variables were summarized by contingency tables (frequencies and proportions (percentages)). Continuous variables were summarized by mean, standard deviation, standard error, median, quartiles and range, minimum and maximum. Day 1 sTREM-1 levels (referred to separately at baseline, or admission to the ICU) were also described (mean, standard deviation, standard error, median, quartiles and range, minimum and maximum) and separately within defined populations and subgroups. 28-day mortality was estimated within each quartile of the distribution of day 1 sTREM-1 levels. Time to death was analyzed with proportional hazards COX regression models. Areas under the receiver operating characteristic curve (AUC) with 95% CI for predicting 28-day mortality from day 1 levels of sTREM-1 were calculated. The optimal sTREM-1 cutoff was estimated based on i) minimization of the distance between the point (0,1) in the upper left corner of the ROC space and any point on the ROC curve, and ii) Youden index. Boxplots of sTREM-1 by survivors / non-survivors and RRT (renal replacement therapy) were plotted. sTREM-1 data were log-transformed where appropriate. The association of sTREM-1 levels with day 1 and 28-day mortality was assessed in univariate and multivariate logistic regression models adjusting for sTREM-1 at baseline (day 1) and adjusting for other prognostic factors (age, sex, cardiac comorbidities, non-cardiac comorbidities and lactate (maximum or minimum on day 1), SOFA at D1, APACHEII at D1, and SAPSII at D1). result sTREM-1 is a prognostic marker in patients with septic shock: results from the AdrenOSS cohort
[0359] The demographics and general baseline characteristics of patients in the whole population and in each sTREM-1 quartile are shown in Table 1 below. No significant differences were observed in patients among the four sTREM-1 quartile groups (Q1, Q2, Q3, and Q4) for baseline characteristics, age, sex, BMI (body mass index), type of ICU admission, source of sepsis, medical history, and physiological values at admission. The first quartile group, i.e., Q1, includes patients with sTREM-1 levels lower than the first quartile (299 pg / mL), i.e., patients with sTREM-1 levels between 42 and 299 pg / mL. The second quartile group, i.e., Q2, includes patients with sTREM-1 levels between the first quartile (299 pg / mL) and the second quartile (497 pg / mL), i.e., patients with sTREM-1 levels between 299 pg / mL and 497 pg / mL. The third quartile group, Q3, included patients with sTREM-1 levels between the second (497 pg / mL) and third quartile (809 pg / mL), i.e., patients with sTREM-1 levels between 497 pg / mL and 809 pg / mL. The fourth quartile group, Q4, included patients with sTREM-1 levels higher than the third quartile (809 pg / mL), i.e., patients with sTREM-1 levels between 809 pg / mL and 5540 pg / mL. At baseline, there was a significant correlation between sTREM-1 values and lactate levels, arterial pH, creatinine levels, urea levels, and PCT levels. sTREM-1 levels also correlated with renal replacement therapy (RRT), baseline SOFA, SAPSII, and APACHEII scores, and 28- and 90-day mortality. 28-day mortality was 12.2%, 30.1%, 37%, and 49.3% in quartiles Q1, Q2, Q3, and Q4, respectively. Overall mortality was 32%. These results confirm that the level of TREM-1 pathway activation at ICU admission, assessed by measurement of plasma sTREM-1, is associated with a more complicated outcome in patients with septic shock. [Table 1] TIFF0007593644000002.tif230163TIFF0007593644000003.tif229162
[0360] Figure 2A shows the ROC plot. Figure 2B shows the survival of patients over time in the form of a Kaplan-Meier curve. Patients with the lowest sTREM-1 values (Q1 quartile group) had a higher 28-day survival rate than patients with the highest sTREM-1 values (Q2-Q4 quartile group). Survival rates within the sTREM-1 quartile groups were 87.8%, 69.9%, 63%, and 50.7%, from Q1 to Q4, respectively. To predict mortality from the data presented in Table 2 below, the optimal cutoff value was calculated at 408 pg / mL. [Table 2] TIFF0007593644000005.tif80162
[0361] No interactions were observed between sTREM-1 levels and age, sex, lactate, cardiac comorbidities, non-cardiac comorbidities, SOFA, SOFA.4, APACHE2, or SAPS2 (all interactions p>0.1). sTREM-1 was an independent predictor of 28-day mortality, providing additional information to all covariates examined (all p<0.001).
[0362] Non-survivors at 28 and 90 days showed significantly elevated sTREM-1 levels at baseline when compared to sTREM-1 levels at baseline in survivors at 28 and 90 days (Figure 3A-B). Interestingly, sTREM-1 values on day 1 correlated with sTREM-1 values on days 2 and 3 (Spearman's rank correlation r=0.91 (CI: 0.88, 0.93; p<0.001; n=260), and Spearman's rank correlation r=0.86 (CI: 0.81, 0.9); p<0.001; n=219)), and sTREM-1 values on day 2 correlated with sTREM-1 values on day 3 (Spearman's r=0.96 (CI: 0.95, 0.97; p<0.001; n=213)). sTREM-1 values on days 2 and 3 were still found to be elevated in non-survivors at 28 and 90 days compared to sTREM-1 values on days 2 and 3 in survivors at 28 and 90 days (Figures 4A-B and 5A-B). sTREM-1 values on days 1, 2, and 3 were also associated with renal replacement therapy (RRT) at admission and throughout the stay (Figures 6A-C).
[0363] Of all parameters examined, sTREM-1 was shown to correlate better with SOFA score (Spearman's rank correlation r = 0.42, p < 0.001; n = 254).
[0364] All these results tend to indicate that sTREM-1 levels are associated with severity, renal replacement therapy, and mortality. Thus, these results confirm that sTREM-1 levels can be used as a reliable biomarker to identify patients at risk for complicated outcomes. Example 3: material and method sTREM-1 Measurement: A Validated ELISA Method for the Quantitative Measurement of sTREM-1 in Human K2-EDTA Plasma
[0365] Quantitative measurement of sTREM-1 was performed using the method described in Example 2. Evaluating sTREM-1 in a Phase IIa clinical trial with nangibotide in patients with septic shock (NCT03158948)
[0366] This was a European prospective observational multinational study involving 14 centers in 4 countries (France, Belgium, the Netherlands, and Spain). Patients were recruited from July 2017 to June 2018. The study was carried out in accordance with the principles stated in the Declaration of Helsinki and its subsequent amendments, the guidelines of the International Conference on Harmonization on Good Clinical Practice, and the requirements of national drug and data protection laws, as well as other applicable regulatory requirements.
[0367] This was a randomized, double-blind, two-stage, placebo-controlled trial. As described in Figure 7, the study consisted of two stages with a similar treatment regimen, testing 0.3 mg / kg / h, 1.0 mg / kg / h, or 3.0 mg / kg / h of nangibotide (corresponding to peptide LR12, with the amino acid sequence set forth in SEQ ID NO: 9, also known as motrem) compared to placebo. All patients diagnosed with septic shock were considered for inclusion in the study. All potential study patients underwent standard care management procedures. Patients with evidence of septic shock according to the Sepsis-3 definition (Singer et al., JAMA 2016) (i.e., patients suffering from sepsis and (i) having persistent hypotension requiring vasopressors to maintain mean arterial pressure ≥ 65 mmHg, and (ii) having serum lactate levels above 2 mmol / L (18 mg / dL) despite adequate volume resuscitation) were considered eligible.
[0368] Exclusion criteria were previous episode of septic shock (vasopressor administration) during the current hospitalization, concurrent immunosuppression as an underlying disease, solid organ transplant requiring immunosuppressive therapy, known pregnancy, long QT syndrome (QTc ≥ 440 ms), shock from any other cause, e.g., hypotension related to gastrointestinal bleeding, ongoing documented or suspected endocarditis, history of prosthetic heart valves, end-stage neurological disease, end-stage liver cirrhosis (Child-Pugh class C), Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥ 34, end-stage chronic renal disease requiring chronic dialysis, home oxygen therapy regularly > 6 h / day, severe obesity (body mass index [BMI] ≥ 40), recent cardiopulmonary resuscitation (within the current hospitalization), moribund patients, and a decision to limit complete care taken before obtaining informed consent.
[0369] After screening for eligibility, patients were randomized to one of the treatment groups. Patients then received a loading dose of 5 mg / kg nangibotide over 15 minutes, followed by a continuous intravenous (iv) infusion of nangibotide or a matching placebo in addition to standard of care. Treatment with the study drug was initiated as soon as possible, but no later than 24 hours after the onset of septic shock, defined by the initiation of vasopressor therapy. Patients were treated until 12 (± 2) hours after resolution of septic shock (defined as cessation of vasopressors), with a maximum treatment duration of 5 days (120 hours).
[0370] Phase 1 was conducted to investigate ascending doses of nangibotide or placebo in a sequential design in cohorts of four patients (randomized 3:1). After cohort completion, safety and PK data were reviewed by an independent Data Safety Monitoring Board (DSMB) and the study could proceed to the next cohort / phase. Phase 2 investigated three doses of nangibotide in a randomized, balanced parallel-group design with up to three doses of nangibotide and a placebo arm. Only dose arms of nangibotide that were deemed safe and well tolerated during Phase 1 were administered in Phase 2. Phase IIa PK Analysis Method Using Nangibotide
[0371] Nangibotide blood concentrations were determined by a validated LC-MS / MS method according to the European Medicines Agency's (EMA) guideline on validation of analytical methods for drug concentrations in biological samples EMEA / CHMP / EWP / 192217 / 2009, version EMA / 275542 / 2014. The peptide was stabilized in blood samples by treatment with 10% trichloroacetic acid solution (1500 mg / mL, 4 °C) and centrifugation (3500 g, 10 min, 4 °C) to collect and freeze the supernatant before analysis. The lower limit of quantification (LLOQ) and upper limit of quantification (ULOQ) were 5 ng / mL and 1000 ng / mL, respectively. The standard curve was linear in the range of 5 ng / mL to 1000 ng / mL, with a correlation coefficient greater than 0.995. During three validations of quality control (QC) of nangibotide, intra- and inter-run precision and accuracy of + / -20% LLOQ and + / -15% (other levels up to ULOQ) were achieved. Immunogenicity assessment
[0372] Anti-nangibotide antibodies in serum were assessed at baseline, day 8 and day 28 by an indirect ELISA method validated according to the method described by Shankar et al. (J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81) and the EMA guidance on immunogenicity assessment of therapeutic proteins of biotechnology origin (EMEA / CHMP / BMWP / 14327 / 2006, issued April 2008). Screening samples determined to be positive were further evaluated using a confirmatory assay in which a cut point was established to have 0.1% false positive samples (Shankar et al., J Pharm Biomed Anal. 2008 Dec 15;48(5):1267-81). Validation of the method showed no drug interference. The sensitivity of the assay was established to be 0.3125 μg / mL. Statistical Analysis of Phase IIa with Nangibotide
[0373] Adverse events (AEs) were coded using the MedDRA dictionary version 18.1. Treatment-emergent adverse events (TEAEs) were summarized and enumerated. Analysis was performed on 49 patients with septic shock. Demographics and baseline characteristics were summarized in a descriptive manner within each population. Categorical variables were summarized by contingency tables (frequency and proportion (percentage)). sTREM-1 levels on day 1 were also described (mean, standard deviation, standard error, median, quartiles and range, minimum and maximum). Mortality was reported as frequency and proportion (percentage). For continuous endpoints, i.e., sequential organ failure assessment (SOFA), missing data were imputed using the last observation extrapolation method (LOCF, Last Observation Carry-Forward). Time-to-event analyses, i.e., duration of invasive mechanical ventilation (IMV), duration of continuous renal replacement therapy (CRRT), survival, and censored data techniques were used. Additionally, sensitivity analyses of time to event data (excluding survival) were performed using censoring at the upper limit of the corresponding observation period (i.e., day 28 or day 90). Days alive and free of any vasopressor, IMV (invasive mechanical ventilation) or CRRT (continuous renal replacement therapy) were calculated as the total number of calendar days from treatment start (day 0) to visit day 28 when the subject was alive and did not require any vasopressor, IMV or CRRT treatment. The following comparisons were made: each nangibotide dose group against placebo, all nangibotide dose combinations against placebo, and dose response using ordinal trend tests. Exploratory composite endpoints: incidence (number and percentage) of patients alive and free of vasopressors, IMV and CRRT at day 28 were summarized by treatment and compared between treatments using Fisher's exact test. For pharmacodynamic markers, log-transformed data were expressed as percentage change from baseline at day 5 or end of infusion (EOI) if the infusion was stopped before day 5. High and low sTREM-1 patients were defined as those who had sTREM-1 blood concentrations above and below the population median (i.e., 433 pg / mL, respectively) on admission to the ICU (baseline or day 0)."All nangibotide" refers to analyses obtained by pooling data from the 0.3 mg / kg / h, 1 mg / kg / h, and 3 mg / kg / h nangibotide treatment groups. result Patient demographics and baseline characteristics
[0374] Fifty patients were randomized, and 49 were treated (one patient died before dosing). As shown in Figure 8, 12 patients were randomized in each group, with one additional patient in the 0.3 mg / kg / h group. All discontinuations were due to death. Thirty-six patients survived to day 90. Both groups were well balanced with respect to baseline characteristics (age, sex, race, weight, height, BMI not shown). The mean age was 64 years (± 13 years). On average, patients were under vasopressors for 15 hours (range 3 hours to 24 hours) before starting treatment, with no significant difference between groups, and 15 of 49 patients were treated after receiving vasopressors between 3 and 12 hours (30.6%). Patient demographics and general baseline characteristics are shown in Table 3 below. [Table 3] safety
[0375] No adverse events (AEs) led to treatment discontinuation. The number of serious adverse events / AEs (SAEs / AEs) and the number of patients with SAEs / AEs were similar in the nangibotide and placebo groups. Proportionately, the number of SAEs and the number of patients with SAEs were higher in the placebo group. The number of AEs and the number of patients with high severity AEs were similar between treatment groups, but proportionally higher in the placebo group. The number of AEs by system organ class was similar between treatment groups. AEs related to infections and cardiac disorders were proportionally higher in the nangibotide group. The most frequent (>10%) AEs were atrial fibrillation, anemia, pleural effusion, and thrombocytopenia. The incidence of atrial fibrillation and thrombocytopenia was proportionally higher in the nangibotide group. Two suspicious unexpected serious adverse reactions (SUSARs) without obvious explanation were reported, both within the nangibotide treatment group. There was no clear explanation indicating a relationship to nangibotide treatment. As shown in Table 4 below, nangibotide was safe and well tolerated up to 3 mg / kg / h. [Table 4] Pharmacokinetics
[0376] For all subjects in all groups, pre-dose samples (blood samples taken before the start of the nangibotide infusion, i.e., baseline samples) contained no quantifiable nangibotide. Mean nangibotide blood concentrations over time obtained from each group (i.e., patients receiving 0.3 mg / kg / h, patients receiving 1.0 mg / kg / h, and patients receiving 3.0 mg / kg / h) from the start of the intravenous infusion are shown in Figure 9A. Nangibotide exhibited linear behavior from the start to the end of the intravenous infusion. Nangibotide blood concentrations were found to be dose-proportional. After the end of the infusion, the product was quickly cleared (Figure 9B), demonstrating a pharmacokinetic pattern similar to that previously observed in healthy volunteers. No drug was detected in the blood 2 hours after the end of the infusion, so no sustained pharmacological effects are predicted after this period. mortality rate
[0377] There was a consistent trend in the proportion of patients who died favoring the nangibotide treatment group compared with placebo. Indeed, the pooled all-cause mortality rate at day 28 was 14% (5 / 37) in the nangibotide group and 25% (3 / 12) in the placebo group (see Table 5 below). [Table 5]
[0378] In the subgroup with baseline sTREM-1 levels above the median, i.e., above 433 pg / mL, all deaths were sepsis-related. In this group, all deaths occurred during the first week of the study. Mortality at day 5 was calculated as 40% (2 / 5) and 20% (4 / 20) in the placebo and nangibotide groups, respectively (see Table 6 below). [Table 6] Organ failure parameters
[0379] Although no statistically significant differences in clinical parameters were found between the nangibotide treatment groups compared to the placebo group, a consistent numerical trend in favor of nangibotide was observed in the reduction of SOFA scores during the first 5 days (more reduction in treatment groups compared to the placebo group). For example, as shown in Table 7 below, the difference in SOFA scores for the "all nangibotide" group compared to the "placebo" group was -0.70 (95% CI: -2.41, 1.01), ranging from -1.66 (95% CI: -3.73, 0.40) to 0.34 (95% CI: -1.76, 2.44) for doses of 0.3-3 mg / kg / h. [Table 7]
[0380] Interestingly, these differences were more significant in the baseline high sTREM-1 subgroup (patients with baseline sTREM-1 levels above the median, i.e., above 433 pg / mL). Indeed, as shown in Table 8 below, the difference in SOFA scores in the "all nangibotide" group compared to the "placebo" group was -1.5 (95% CI: -3.83, 0.84), ranging from -2.85 (95% CI: -5.68, -0.02; p=0.0487) to -0.16 (95% CI: -2.80, 2.48) for doses of 0.3 to 3 mg / kg / h. [Table 8]
[0381] Conversely, these differences were less significant in the baseline low sTREM-1 subgroup (patients with sTREM-1 levels below the median at baseline, i.e., less than 433 pg / mL). Indeed, as shown in Table 9 below, the difference in SOFA scores in the "all nangibotide" group compared to the "placebo" group on day 5 was -0.18 (95% CI: -2.95, 2.59), ranging from -0.71 (95% CI: -3.97, 2.54) to 0.12 (95% CI: -3.70, 3.94) for doses of 0.3 to 3 mg / kg / h. [Table 9]
[0382] Unexpectedly, as shown in Figure 10, an inverse dose response was observed, with a more significant difference in the low dose group, 0.3 mg / kg / h (-2.85, p=0.0487), compared to the high dose group, 3 mg / kg / h (-0.16, p=0.9007).
[0383] These results indicate that the overall treatment-related decrease in SOFA score observed in the entire population was driven by a decrease in SOFA score in patients with the highest baseline sTREM-1 values (above the median, i.e., above 433 pg / mL), and no between-group differences were observed in the group of patients with low baseline sTREM-1 values (below the median, i.e., below 433 pg / mL).
[0384] Similarly, no statistically significant differences in clinical parameters were found between the nangibotide treatment groups compared with the placebo group, but consistent numerical trends in favor of nangibotide were observed for vasopressor use, invasive mechanical ventilation (IMV) use, and renal replacement therapy (RRT) use.
[0385] In the baseline low sTREM-1 subgroup, the difference in days alive and free of vasopressors in the "all nangibotide" group compared with the "placebo" group was 0.64 (95% CI: -5.78, 7.07; p = 0.8368) for doses of 0.3 to 3 mg / kg / h, ranging from 2.29 (95% CI: -5.30, 9.87; p = 0.5369) to 0.07 (95% CI: -8.83, 8.97; p = 0.9868). In the baseline high sTREM-1 subgroup, the difference in days alive and free of vasopressors in the "all nangibotide" group compared with the "placebo" group was 2.94 (95% CI: -9.36, 15.25; p = 0.6243) for doses of 0.3 to 3 mg / kg / h, ranging from 4.07 (95% CI: -10.81, 18.94; p = 0.5757) to -0.48 (95% CI: -14.48, 13.53; p = 0.9444).
[0386] In the overall population, the difference in days alive without IMV (invasive mechanical ventilation) in the "all nangibotide" group compared with the "placebo" group was 1.33 (95% CI: -6.20, 8.89; p = 0.7240) for doses of 0.3 to 3 mg / kg / h, ranging from 2.32 (95% CI: -6.75, 11.40; p = 0.6091) to -2.08 (95% CI: -11.34, 7.17; p = 0.6524). In the baseline low sTREM-1 subgroup, the difference in days alive without IMV in the "all nangibotide" group compared with the "placebo" group was -1.30 (95% CI: -9.92, 7.32; p = 0.7568) for doses of 0.3 to 3 mg / kg / h, ranging from 3 (95% CI: -7.18, 13.18; p = 0.5455) to -6.32 (95% CI: -18.25, 5.61; p = 0.2823). In the baseline high sTREM-1 subgroup, the difference in days alive without IMV in the "all nangibotide" group compared with the "placebo" group was 5.63 (95% CI: -7.24, 18.51; p = 0.3732) for doses of 0.3 to 3 mg / kg / h, ranging from 2.63 (95% CI: -12.93, 18.20; p = 0.7285) to 4.30 (95% CI: -10.35, 18.95; p = 0.5483).
[0387] In the overall population, the difference in days alive free of CRRT (continuous renal replacement therapy) in the "all nangibotide" group compared with the "placebo" group was 2.70 (95% CI: -4.46, 9.86; p = 0.4516) for doses of 0.3 to 3 mg / kg / h, ranging from 4.10 (95% CI: -4.53, 12.73; p = 0.3435) to 1.50 (95% CI: -7.30, 10.30; p = 0.7330). In the baseline low sTREM-1 subgroup, the difference in days alive free of CRRT in the "all nangibotide" group compared with the "placebo" group was 0.77 (95% CI: -4.72, 6.25; p = 0.7738) for doses of 0.3 to 3 mg / kg / h, ranging from 1.43 (95% CI: -5.04, 7.90; p = 0.6502) to 0.89 (95% CI: -6.70, 8.48; p = 0.8086). In the baseline high sTREM-1 subgroup, the difference in days alive free of CRRT in the "all nangibotide" group compared with the "placebo" group was 7.85 (95% CI: -5.22, 20.91; p = 0.2254) for doses of 0.3 to 3 mg / kg / h, ranging from 8.67 (95% CI: -7.13, 24.46; p = 0.2666) to 7.37 (95% CI: -7.49, 22.24; p = 0.3140).
[0388] These trends were magnified in patients with high levels of circulating sTREM-1 at baseline (above the median, i.e., above 433 pg / mL), as shown in Figure 11. Furthermore, in the "all nangibotide" group, the proportion of patients alive and not receiving any medical support at day 28 was 70% versus 40% in the "placebo" group. marker
[0389] A trend towards a decrease during treatment in circulating levels of endothelial injury markers (Ang-2, VCAM-1, VGEFR-1 and E-selectin), inflammatory markers (IL-8, IL-10, MCP-1, TNF-α and IL-10) and sTREM-1 was observed in nangibotide-treated patients, which was more pronounced for Ang-2, IL-6 and sTREM-1 in patients with higher sTREM-1 levels at baseline. For example, when no clear treatment effect was observed in Ang-2 levels in the total population, a trend towards a more pronounced decrease was observed in the "G2" subgroup (i.e., patients with baseline sTREM-1 >433 pg / mL median) when compared to the "All" and "G1" subgroups (i.e., patients with baseline sTREM-1 <433 pg / mL median) in the total population (see FIG. 12). The same trend was observed for IL-6 levels, as shown in FIG. 13. sTREM-1 as a marker of efficacy
[0390] In addition to its value as a qualified biomarker, sTREM-1 was also evaluated as a marker of efficacy of nangibotide in this Phase IIa study. The impact of nangibotide treatment on sTREM-1 dynamics over time was evaluated. As shown in Figure 14A, no clear changes over time were observed in the overall population, but a trend toward decreased sTREM-1 was observed in the subgroup of patients with higher baseline sTREM-1 values. Interestingly, patients with the greatest changes in sTREM-1 also had the greatest decrease in SOFA at day 5 / EOI (end of infusion) (Figure 14B). conclusion
[0391] Nangibotide was shown to be safe and well tolerated in patients with septic shock. In this small exploratory study, a non-significantly lower mortality rate was observed in the nangibotide group. Surprisingly, clinical parameters and mortality showed a clear trend toward a beneficial effect of nangibotide in patients with higher circulating levels of sTREM-1 at baseline.
[0392] Highly variable and controversial results have been published regarding the use of sTREM-1 as a prognostic marker in patients with septic shock. This may be partly due to the lack of a validated and reproducible quantitative assay. Such a method was validated according to the European Medicines Agency's Guideline: Committee for Medicinal Products for Human Use (CHMP) (2011) Guideline on Validation of Analytical Methods for Drug Concentrations in Biological Samples EMEA / CHMP / EWP / 192217 / 2009Rev.1 Corr.2. The validated method has been described above (see Materials and Methods) and was used for the retrospective measurement of sTREM-1 levels in two independent clinical cohorts (the AdrenOSS cohort and the cohort of a Phase IIa clinical trial with nangibotide).
[0393] Interestingly, comparable data were obtained in these two independent European cohorts of 293 and 49 patients, as shown below. [Table 10]
[0394] Baseline sTREM-1 levels were associated with 28-day mortality: 12% and 8% mortality rates were observed in the sTREM-1 quartile Q1 subgroup, and 49% and 42% mortality rates were observed in the sTREM-1 quartile Q4 subgroup. Median values were 497 pg / mL in the AdrenOSS cohort and 433 pg / mL in the phase IIa cohort with nangibotide, with minimum / maximum values (pg / mL) of 42 / 5540 pg / mL and 154 / 1960 pg / mL, respectively, suggesting a similar distribution between the two cohorts.
[0395] These results confirm the need for validated methods to collect reliable data across different cohorts, and that such methods allow reference values from reference populations to be used to derive predefined sTREM-1 values that can be used in further studies.
[0396] Overall, this study aimed to evaluate the value of sTREM-1 level assessment for patient selection before nangibotide administration. Indeed, data from the literature (Charles et al., BMC Infect Dis. 2016 Oct 12;16(1):559) showing that high sTREM-1 values at baseline were associated with complex outcomes are not consistent with previous clinical data (Gibot et al., Crit Care Med. 2005 Apr;33(4):792-6) in which low sTREM-1 values at baseline were associated with complex outcomes. Thus, it remained unclear whether sTREM-1 values were associated with severity and clinical outcomes. The mechanism of sTREM-1 release was also unclear.
[0397] In this study, we demonstrate for the first time that the release of sTREM-1 depends on the activation of TREM-1. Therefore, sTREM-1 can be used as a reliable surrogate for the activation of the TREM-1 pathway. This may therefore make it possible to identify patients who are most likely to benefit from anti-TREM-1 therapeutic approaches such as nangibotide (corresponding to peptide LR12 having the amino acid sequence set forth in SEQ ID NO: 9).
[0398] Using a guideline-based validated method, we also showed in two independent cohorts that high sTREM-1 levels correlated with severity and mortality in patients with septic shock, thus confirming that sTREM-1 is a reliable biomarker of severity and may allow the identification of patients at risk for complicated outcomes. Indeed, we found that baseline sTREM-1 blood levels, i.e. within 24 hours after diagnosis of septic shock, correlated with severity.
[0399] We also conducted a subgroup analysis in a Phase IIa clinical trial evaluating the safety and tolerability of nangibotide in patients with septic shock. The study compared the efficacy of nangibotide between patients with baseline sTREM-1 values below a given sTREM-1 value, defined herein as the median, and patients with baseline sTREM-1 values above this given sTREM-1 value. The efficacy of nangibotide was confirmed to be more pronounced in patients with baseline sTREM-1 values above a given sTREM-1 value, i.e., above the median (>433 pg / mL). This was observed in pharmacodynamic parameters (endothelial and inflammatory biomarkers), use of medical support (IMV, CRRT, vasopressors), and SOFA scores.
[0400] The low pharmacological activity of nangibotide in patients with baseline sTREM-1 levels below the given sTREM-1 value cannot be explained by toxicity and side effects, since nangibotide was well tolerated at all doses tested and no adverse events related to nangibotide treatment were observed at the highest dose. No anti-nangibotide antibodies were found in the serum of the patients, which also indicates that this apparently low pharmacological activity in these patients cannot be related to the presence of anti-nangibotide neutralizing antibodies that would have been able to inhibit nangibotide. Nangibotide blood concentrations were dose-proportional and within the same range as previously observed in healthy volunteers, i.e., there was no abnormal pharmacokinetic profile of nangibotide in the patients, which could also explain the differences between groups. The product was rapidly eliminated after the end of the infusion, which also means that these differences cannot be explained by any sustained pharmacological activity.
[0401] Overall, these results confirm that sTREM-1 is a reliable companion diagnostic marker for patient eligibility and administration of TREM-1 inhibitors (e.g., nangibotide).
Claims
1. An in vitro method for determining whether a human subject suffering from an acute inflammatory disorder is likely to respond to nangibotide, comprising: a) measuring the level of soluble Triggering Receptors Expressed on Myeloid cells-1 (sTREM-1) in a biological sample from said human subject prior to administration of nangibotide; b) comparing the level of sTREM-1 measured in step a) with a predetermined sTREM-1 value, wherein the level of sTREM-1 measured in step a) higher than the predetermined sTREM-1 value indicates that the human subject suffering from an acute inflammatory disorder is likely to respond to nangibotide; the acute inflammatory disorder is septic shock, sepsis, or systemic inflammatory response syndrome (SIRS); The method, wherein nangibotide is a TLT-1 peptide having the amino acid sequence set forth in SEQ ID NO:
9.
2. 2. The in vitro method of claim 1, wherein said predetermined sTREM-1 value of step b) is obtained from a reference population.
3. 3. The in vitro method of claim 2, wherein the reference population is a population of human patients suffering from an acute inflammatory disorder, which is septic shock, sepsis, or SIRS.
4. 4. The in vitro method of claim 2 or claim 3, wherein the predetermined sTREM-1 value of step b) is the median value of sTREM-1 in the reference population or the third quartile of sTREM-1 in the reference population.
5. 5. The in vitro method of any one of claims 1 to 4, wherein the level of sTREM-1 measured in step a) is measured within the first 24 hours after diagnosis or hospitalization of the human subject for an acute inflammatory disorder, which is septic shock, sepsis, or SIRS.
6. The in vitro method according to any one of claims 1 to 5, wherein the biological sample is a blood sample, a serum sample or a plasma sample.
7. The in vitro method of any one of claims 1 to 6, wherein the level of sTREM-1 measured in step a) is the protein level.
8. 8. The in vitro method of claim 7, wherein the protein level of sTREM-1 measured in step a) is measured by ELISA, electrochemiluminescence immunoassay (ECLIA) or enzyme-linked fluorescence assay (ELFA).
9. The in vitro method according to any one of claims 1 to 8, wherein the acute inflammatory disorder is septic shock.
10. 10. The in vitro method according to any one of claims 1 to 9, wherein the human subject is suffering from organ dysfunction defined as an acute change in Sequential Organ Failure Assessment (SOFA) score of at least 2 points.
11. The in vitro method of any one of claims 1 to 10, wherein the human subject suffering from septic shock, sepsis, or SIRS susceptible to response to nangibotide is a human subject susceptible to a decrease in Sequential Organ Failure Assessment (SOFA) score following administration of said nangibotide.
12. 10. The in vitro method of claim 9, wherein the human subject suffering from septic shock amenable to response to nangibotide is a human subject suffering from septic shock amenable to reversal of hypotensive shock within or after a period of administration of the nangibotide, where hypotensive shock reversal is defined as the absence of any vasopressor therapy for a 24 hour period.
Citation Information
Patent Citations
A method of diagnosing an infectious disease by measuring soluble trem-1 levels in a sample
JP2007519916A
Inhibitory peptides derived from TREM-like transcript 1 (TLT-1) and their use
JP2013523140A
